





Hotline Page #	Test Number	Summary of Changes by Test Name	Name Change	Methodology	Performed/Reported Schedule	Specimen Requirements	Reference Interval	Interpretive Data	Note	CPT Code	Component Change	Other Interface Change	New Test	Inactive
10	<u>2011967</u>	Allergens, Pediatric, Common Profile IgE											х	
58	<u>0051786</u>	Alport Syndrome, X-linked (COL4A5) Sequencing												х
11	<u>3003480</u>	Antithrombospondin Type-1 Domain-Containing 7A (THSD7A) Antibody, IgG with Reflex to Titer											x	
12	<u>3003393</u>	BCL-10 by Immunohistochemistry											х	
58	<u>2010113</u>	Beta Globin (HBB) Deletion/Duplication												х
58	<u>2011450</u>	Carisoprodol and Meprobamate, Serum or Plasma, Quantitative												x
12	<u>2012219</u>	Carisoprodol and Meprobamate, Urine, Quantitative			x									
12	<u>2011114</u>	CBFB-MYH11 inv(16) Detection, Quantitative									х			
13	2008114	Celiac Disease Reflexive Cascade		х		х	х							
58	2012717	CHARGE Syndrome (CHD7) Sequencing, Fetal												х
58	2012609	CHARGE Syndrome, CHD7 Sequencing												х
14	3003423	Chymotrypsin by Immunohistochemistry											х	
14	0051720	Complement Factor B			х									
14	2011480	Copper, Random Urine					х							
15	0020461	Copper, Urine					х							
15	0060046	Cryptosporidium and Coccidia Exam, Fecal	х	х					х	х				
16	3003259	Cytokine Panel 13, CSF											х	
17	3003144	Deletion/Duplication Analysis by MLPA											х	
17	<u>2002693</u>	Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using <i>Crithidia luciliae</i>)				x								
58	<u>2010696</u>	EIF2AK4-Associated Disorders (EIF2AK4) Sequencing												x
17	<u>0051626</u>	Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgA					x					x		
18	<u>0051627</u>	Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgG and IgA					x					x		
19	<u>3002737</u>	FISH, Interphase, CD138+ Cells											х	
20	<u>0099906</u>	Fluphenazine				х	х	х						
20	<u>0099640</u>	Haloperidol					Х							
21	<u>0025055</u>	Heavy Metals Panel 6, Urine with Reflex to Arsenic Fractionated					x							
21	<u>2005792</u>	Hemoglobin Evaluation Reflexive Cascade									х	х		
22	<u>3002989</u>	Hepatitis Panel, Acute with Reflex to HBsAg Confirmation and Reflex to HCV by Quantitative NAAT											х	



Hotline Page #	Test Number	Summary of Changes by Test Name	Name Change	Methodology	Performed/Reported Schedule	Specimen Requirements	Reference Interval	Interpretive Data	Note	CPT Code	Component Change	Other Interface Change	New Test	Inactive
23	<u>3000894</u>	Hereditary Hemolytic Anemia Cascade											x	
58	<u>0051381</u>	Hereditary Hemorrhagic Telangiectasia (ACVRL1 and <i>ENG</i>) Sequencing												x
24	<u>3001842</u>	Hereditary Myeloid Neoplasms Panel, Sequencing											x	
25	<u>0092283</u>	Herpes Gestationis Factor (Complement-Fixing Basement Membrane Zone Antibody IgG)				x			x					
58	<u>2012482</u>	HLA-A by Next Generation Sequencing												х
58	<u>2012486</u>	HLA-B by Next Generation Sequencing												х
58	<u>2012490</u>	HLA-C by Next Generation Sequencing												х
58	<u>2012502</u>	HLA-DPB1 by Next Generation Sequencing												х
58	<u>2012498</u>	HLA-DQB1 by Next Generation Sequencing												х
58	<u>2001728</u>	HNPCC/Lynch Syndrome Deletion/Duplication												х
26	<u>0050980</u>	Humoral Immunity Panel I		Х		х	х							
27	<u>3003486</u>	Immunoglobulin D, Serum											x	
27	<u>3003485</u>	Immunoglobulin G, CSF											x	
28	<u>0050340</u>	Immunoglobulin A		Х		х	х							
28	<u>0093149</u>	Immunoglobulin A Subclasses (1 and 2)		Х		х	х							
29	<u>0050341</u>	Immunoglobulin A, CSF		Х		х								
58	<u>0050525</u>	Immunoglobulin A, Saliva												х
58	<u>0099200</u>	Immunoglobulin D, Serum												х
29	<u>0050350</u>	Immunoglobulin G		Х		х	х							
58	<u>0050571</u>	Immunoglobulin G Subclass 1												х
58	<u>0050572</u>	Immunoglobulin G Subclass 2												х
58	<u>0050573</u>	Immunoglobulin G Subclass 3												х
29	<u>0050576</u>	Immunoglobulin G Subclass 4		х	x	х	x							
30	<u>0050577</u>	Immunoglobulin G Subclasses (1, 2, 3, 4)		х	x	x	х	x						
58	<u>0050670</u>	Immunoglobulin G, CSF												х
31	<u>0050676</u>	Immunoglobulin G, CSF Index		х		x	x					х		
31	<u>0050680</u>	Immunoglobulin G/Albumin Ratio, CSF		Х		х								
32	<u>0050355</u>	Immunoglobulin M		х		х	x							
32	0050356	Immunoglobulin M, CSF		x	x	x								
33	0050630	Immunoglobulins (IgA, IgG, IgM), Quantitative		х		x	x							
33	<u>0050631</u>	Immunoglobulins, CSF Quantitative		х		x	х							
34	0070413	Inhibin B				х	х							
34	<u>3003261</u>	Interleukin 2 Receptor, Soluble, CSF											x	



Hotline Page #	Test Number	Summary of Changes by Test Name	Name Change	Methodology	Performed/Reported Schedule	Specimen Requirements	Reference Interval	Interpretive Data	Note	CPT Code	Component Change	Other Interface Change	New Test	Inactive
58	<u>2004680</u>	Interleukin 28 B (IL28B)-Associated Variants, 2 SNPs												x
35	<u>3003260</u>	Interleukin 6, CSF											х	
35	<u>3003506</u>	Kappa/Lambda Light Chain Panel by in situ Hybridization on Paraffin											X	
36	<u>3003525</u>	Kappa/Lambda Light Chain Panel by In Situ Hybridization Stain Only											x	
58	<u>2002888</u>	Kappa/Lambda Light Chain Panel by in situ Hybridization, Paraffin												x
58	2013595	Kappa/Lambda Light Chain Panel by In Situ Hybridization, Stain Only												x
36	<u>3003311</u>	Kratom (Mitragynine) - Screen with Reflex to Confirmation/Quantitation, Urine											x	
58	<u>3001379</u>	Liver Fibrosis - FibroMeter Vibration Controlled Transient Elastography (FibroMeter plus FibroScan VCTE)												X
37	<u>0051692</u>	Mannose Binding Lectin				x								
37	<u>3000146</u>	Maternal Screening, Sequential, Specimen #1, hCG, PAPP-A, NT									x			
37	<u>3000144</u>	Maternal Serum Screen, Alpha Fetoprotein									х			
37	<u>3000143</u>	Maternal Serum Screen, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (Quad)									x			
37	<u>3000145</u>	Maternal Serum Screen, First Trimester, hCG, PAPP-A, NT									x			
37	<u>3000147</u>	Maternal Serum Screening, Integrated, Specimen #1, PAPP-A, NT									х			
38	<u>3003477</u>	Membranous Nephropathy Comprehensive Autoantibody Panel											x	
58	<u>2011521</u>	Meprobamate, Serum or Plasma, Quantitative												х
38	<u>0050184</u>	Metanephrines, Plasma (Free)				x								
39	<u>2002715</u>	Monoclonal Protein Study, Expanded Panel, Serum				х	х							
40	<u>2007967</u>	Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot		x		x	x							
43	<u>0051225</u>	Motor Neuropathy Panel		х			х							
45	<u>3003566</u>	Mucopolysaccharidoses Type 1/2, Total Heparan Sulfate and NRE (Sensi-Pro®) Quantitative, Serum or Plasma											x	
46	<u>3003552</u>	Mucopolysaccharidoses Type 1/2, Total Heparan Sulfate and NRE (Sensi-Pro®) Quantitative, Urine											x	



Hotline Page #	Test Number	Summary of Changes by Test Name	Name Change	Methodology	Performed/Reported Schedule	Specimen Requirements	Reference Interval	Interpretive Data	Note	CPT Code	Component Change	Other Interface Change	New Test	Inactive
47	<u>3003487</u>	Mucopolysaccharidoses Type 4A/6 Total Chondroitin Sulfate and Dermatan Sulfate with NRE (Sensi-Pro®) Quantitative, Serum											x	
48	<u>3003539</u>	Mucopolysaccharidoses Type 4A/6 Total CS-DS and NRE (Sensi-Pro®) Quantitative, Urine											x	
58	<u>2007599</u>	Mucopolysaccharidosis Type 1, Total HS and NRE (Sensi-Pro®) Quantitative, Serum or Plasma												x
58	<u>2007488</u>	Mucopolysaccharidosis Type 1, Total HS and NRE (Sensi-Pro®) Quantitative, Urine												x
58	<u>2008775</u>	Mucopolysaccharidosis Type II, Total HS and NRE (Sensi-Pro®) Quantitative, Serum or Plasma												x
58	<u>2009282</u>	Mucopolysaccharidosis Type II, Total HS and NRE (Sensi-Pro®) Quantitative, Urine												x
58	<u>2001952</u>	Neurofibromatosis Type 1 (NF1) Deletion/Duplication												x
48	<u>0092168</u>	Niacin (Vitamin B ₃)				х								
58	<u>2004189</u>	Noonan Syndrome (PTPN11) Sequencing with Reflex to (SOS1) Sequencing												x
49	<u>0080440</u>	Oligoclonal Band Profile		х		х	х					х		
49	<u>0081135</u>	Oligoclonal Bands in CSF and Serum				х								
58	<u>0099289</u>	Organic Acids, Plasma												х
50	<u>2007479</u>	Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine					x				х	x		
51	<u>2009288</u>	Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine					x				X	x		
58	3001760	Pancreatitis (PRSS1) Deletion/Duplication												x
58	3001764	Pancreatitis (SPINK1) Deletion/Duplication												x
51	<u>3000455</u>	Ph-Like Acute Lymphoblastic Leukemia (ALL) Panel by FISH	x											
51	2002871	PML-RARA Detection by RT-PCR, Quantitative									х			
58	0051682	Primary Carnitine Deficiency (SLC22A5) Sequencing												x
52	2002109	Protein Electrophoresis with Reflex to Immunofixation, Serum		x			x							
52	<u>2010138</u>	<i>RUNX1-RUNX1T1</i> (<i>AML1-ETO</i>) t(8;21) Detection, Quantitative									x			
58	3001395	SHOX-Related Disorders, Deletion/Duplication												x
58	0081054	Squamous Cell Carcinoma Antigen, Serum												x
53	3003504	Squamous Cell Carcinoma, Serum											x	



Hotline Page #	Test Number	Summary of Changes by Test Name	Name Change	Methodology	Performed/Reported Schedule	Specimen Requirements	Reference Interval	Interpretive Data	Note	CPT Code	Component Change	Other Interface Change	New Test	Inactive
53	<u>0092582</u>	Stachybotrys chartarum/atra Panel II			х									
53	<u>2003128</u>	Tapentadol and Metabolite, Urine, Quantitative			х	х								
54	<u>3003458</u>	Trypsin by Immunohistochemistry											х	
55	<u>3002100</u>	Tuberous Sclerosis Complex Panel, Sequencing and Deletion/Duplication											x	
56	<u>3002096</u>	Tuberous Sclerosis Complex Panel, Sequencing and Deletion/Duplication, Fetal											x	
56	<u>2003184</u>	Vitamin B ₇ (Biotin)				х								
57	<u>2007136</u>	von Willebrand Factor (VWF) Collagen Binding	х		х	x					x	х		

2002647 Acute Lymphoblastic Leukemia (ALL) Panel by FISH, Adult

FISH A ALL

HOTLINE NOTE: Name change only.

2002719 Acute Lymphoblastic Leukemia (ALL) Panel by FISH, Pediatric

FISH P ALL

HOTLINE NOTE: Name change only.



New Test	<u>3002714</u>	Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing	AML NGS
Click for Pricing	g		
İ	Additional Tec	nnical Information	
Methodology: Performed: Reported:	Massively Paralle Varies 12-14 days	el Sequencing	
Specimen Required	I: <u>Collect:</u> Lavende <u>Specimen Prepar</u> . Fresh-frozen Ti : Separate specime <u>Storage/Transpor</u> Fresh-frozen Ti : <u>Unacceptable Co</u> <u>Stability (collecti</u> Unacceptable Fresh-frozen Ti :	r (EDTA), Green (sodium heparin) Bone Marrow (EDTA) or Bone Marrow (sodium heparin), ation: Whole Blood and Bone Marrow: Transport 3 mL whole blood. (Min: 1.5 mL) ssue: Transport 5 mg fresh-frozen tissue. (Min: 5 mg) ns must be submitted when multiple tests are ordered <u>t Temperature:</u> Whole Blood or Bone Marrow: Refrigerated. ssue: Frozen. <u>nditions:</u> Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue <u>on to initiation of testing):</u> Whole Blood or Bone Marrow: Ambient: 72 hours; Refrigerated ssue: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month	Fresh-frozen tissue. : 1 week; Frozen:
Reference Interv	al: By rej	port	
Interpretive Data	a:		

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Genes tested: ANKRD26, ASXL1, CEBPA, DDX41, DNMT3A, ETV6, FLT3, GATA2, IDH1, IDH2, KIT, KRAS, NPM1*, NRAS, RUNX1, TP53, WT1 * One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.

CPT Code(s): 81450

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

	0050024	Albumin, Body Fluid
--	---------	---------------------

ALB-BF

Methodology: Quantitative Immunoturbidimetry/Quantitative Spectrophotometry

Specimen Required: Collect: Body fluid.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL body fluid to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Remarks: Indicate source on the test request form.

Unacceptable Conditions: Contaminated or grossly hemolyzed specimens. Needle sent with specimen.

Stability (collection to initiation of testing): After separation from cellular material: Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 1 month (avoid repeated freeze/thaw cycles)

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 0050024, Albumin Level Body Fluid from Albumin Level Body Fluid to Albumin, Body Fluid.



0050200 Albumin, CSF

ALB CSF

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: CSF.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly bloody, contaminated, or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 6 months (avoid repeated freeze/thaw cycles)



New Test	<u>2011966</u> A	llergens, Food, Co	mmon Adult Fo	od Profile 13 I	gE	ADULTPAN13
Click for Pricing						
Methodology:	Quantitative ImmunoC	AP Fluorescent Enzyme	Immunoassay			
Performed:	Sun-Sat					
Reported:	1-2 days					
Specimen Required:	Patient Prep: Multiple	patient encounters should	l be avoided.			
	Collect: Serum separat	or tube. Multiple specime	en tubes should be av	voided.		
	Specimen Preparation:	Separate serum from cell	ls ASAP or within 2	hours of collection.	Transfer 1.45 mL s	erum to an ARUP
	Standard Transport Tu	be. (Min: 0.73 mL)				
	Storage/Transport Ten	perature: Refrigerated.				
	Unacceptable Condition	ns: Hemolyzed, icteric, c	r lipemic specimens			
	Stability (collection to	initiation of testing): Afte	er separation from ce	ells: Ambient: 48 ho	ours; Refrigerated: 2	weeks; Frozen: 1 year

Reference Interval:

Reporting Range (reported in kU/L)	Probability of IgE Mediated Clinical Reaction	Class Scoring
Less than 0.10	No significant level detected	0
0.10 - 0.34	Clinical relevance undetermined	0/1
0.35 - 0.70	Low	1
0.71 - 3.50	Moderate	2
3.51 - 17.50	High	3
17.51 - 50.00	Very high	4
50.01 - 100.00	Very high	5
Greater than 100.00	Very high	6

Test Number	Components	Reference Interval	
0050345	Immunoglobulin E	Effective November 17, 2014	
		Age	Reference Interval
		0-5 months	13 kU/L or less
		6-12 months	34 kU/L or less
		1-2 years	97 kU/L or less
		3 years	199 kU/L or less
		4-6 years	307 kU/L or less
		7-8 years	403 kU/L or less
		9-12 years	696 kU/L or less
		13-15 years	629 kU/L or less
		16-17 years	537 kU/L or less
		18 years and older	214 kU/L or less

Interpretive Data:

Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

Note: Allergens included: Walnut (Juglans spp), Clam, Codfish, Corn, Egg White, Milk (Cow), Peanut, Scallop, Sesame Seed, Shrimp, Soybean, Wheat, and IgE Serum Total.

CPT Code(s): 86003 x12; 82785

New York DOH Approved.



New Test	<u>2011967</u>	Allergens, Pediatric,	Common Profile	e IgE	COMPEDPRO
Click for Pricing					
Methodology:	Quantitative Immun	CAP Fluorescent Enzyme	mmunoassay		
Performed:	Sun-Sat				
Reported:	1-2 days				
Specimen Required:	Patient Prep: Multip	e patient encounters should	be avoided.		
	Collect: Serum sepa	rator tube. Multiple specime	n tubes should be avoi	ded.	
	Specimen Preparatio	n: Separate serum from cell	s ASAP or within 2 ho	ours of collection. Transfer 1.35	5 mL serum to an ARUP
	Standard Transport	Tube. (Min: 0.69 mL)			
	Storage/Transport T	emperature: Refrigerated.			
	Unacceptable Condi	tions: Hemolyzed, icteric, or	r lipemic specimens.		
	Stability (collection	to initiation of testing): Afte	r separation from cells	: Ambient: 48 hours; Refrigera	ted: 2 weeks; Frozen: 1 year

Reference Interval:

Reporting Range (reported in kU/L)	Probability of IgE Mediated Clinical Reaction	Class Scoring
Less than 0.10	No significant level detected	0
0.10 - 0.34	Clinical relevance undetermined	0/1
0.35 - 0.70	Low	1
0.71 - 3.50	Moderate	2
3.51 - 17.50	High	3
17.51 - 50.00	Very high	4
50.01 - 100.00	Very high	5
Greater than 100.00	Very high	6

Test Number	Components	Reference Interval		
0050345	Immunoglobulin E	Effective November 17, 2014		
		Age	Reference Interval	
		0-5 months	13 kU/L or less	
		6-12 months	34 kU/L or less	
		1-2 years	97 kU/L or less	
		3 years	199 kU/L or less	
		4-6 years	307 kU/L or less	
		7-8 years	403 kU/L or less	
		9-12 years	696 kU/L or less	
		13-15 years	629 kU/L or less	
		16-17 years	537 kU/L or less	
		18 years and older	214 kU/L or less	

Interpretive Data:

Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: Allergens included: Cat Dander, American Cockroach, Codfish, Dog Dander, Egg White, D. farinae, Alternaria alternata (tenuis), Milk (Cow), Peanut, Soybean, Wheat, and IgE Serum Total.

CPT Code(s): 86003 x11; 82785

New York DOH Approved.



New Test3003480Antithrombospondin Type-1 Domain-Containing 7A (THSD7A)THSD7AAntibody, IgG with Reflex to Titer

Available Now Click for Pricing



Additional Technical Information

Methodology:	Semi-Quantitative Indirect Fluorescent Antibody
Performed:	Tue
Reported:	1-8 days

Specimen Required: Collect: Serum Separator Tube

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL) Storage/Transport Temperature: Refrigerated Unacceptable Conditions: Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval: Less than 1:10

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: If THSD7A Antibody, IgG is positive, then a THSD7A Antibody, IgG titer will be added. Additional charges apply.

CPT Code(s): 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.



New Test	<u>3003393</u>	BCL-10 by Immunohistochemistry
----------	----------------	--------------------------------

BCL-10

INV 16 QNT

Available Now Click for Pricing

Methodology:	Immunohistochemistry
Performed:	Mon-Fri
Reported:	1-3 days

Specimen Required: Collect: Tissue.

<u>Specimen Preparation:</u> Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit recommended but not required. ARUP supply #47808 available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787. (Min: 2 slides) If sending precut slides, do not oven bake.

<u>Storage/Transport Temperature:</u> Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. <u>Unacceptable Conditions:</u> Specimens submitted with non-representative tissue type. Depleted specimens. <u>Stability (collection to initiation of testing):</u> Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: This test is performed as a stain and return (technical) service only.

CPT Code(s): 88342

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

<u>2012219</u>	Carisoprodol and Meprobamate, Urine, Quantitative	CARIS U
Performed:	Thu	
Reported:	1- <mark>8</mark> days	

2011114 *CBFB-MYH11* inv(16) Detection, Quantitative

HOTLINE NOTE: There is a component change associated with this test. Add component 3003496, CBFB-MYH11 Source



2008114 Celiac Disease Reflexive Cascade

Methodology: Quantitative Immunoturbidimetry/Semi-Quantitative Enzyme-Linked Immunosorbent Assay//Semi-Quantitative Indirect Fluorescent Antibody

Specimen Required: Collect: Serum separator tube.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 3 mL serum to an ARUP Standard Transport Tube. (Min: 1.5 mL)

CELIAC REF

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Plasma. Contaminated, hemolyzed, grossly icteric or grossly lipemic specimens. <u>Stability (collection to initiation of testing)</u>: After separation from cells: Ambient: <u>Unacceptable</u>; Refrigerated: 14 days; Frozen: 6 months (avoid repeated freeze/thaw cycles)

Reference Interval:

0050340 Immunoglobulin A Effective February 16, 2021 0050340 Immunoglobulin A Effective February 16, 2021 0050340 Inmunoglobulin A Effective February 16, 2021 0051689 Celiac Disease Dual Antigen Screen Negative - No significant level of detectable IgA or IgG antibodies against human tissue transglutaninase or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DCP) Antibody, IgA Poative - Presence of IgA and/or IgA antibodies against human tissue transglutaninase or gliadin peptide. 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image Pertide (DGP) Antibody, IgG Image Pertide (DGP) Antibody, IgG 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image Pertide (DGP) Antibody, IgG Image Pertide (DGP) Antibody, IgG 0097709 Tissue Transglutaninase (ITG) Antibody, IgA Image Pertide (DGP) Antibody, IgG Image Pertide P	Test Number	Components	Reference Interval	
0°2 years: 21.26 mg/dL 34 years: 47.22 mg/dL 59 years: 30.226 mg/dL 15.18 years: 60.349 mg/dL 19 years and older: 68-408 mg/dL 0051689 Celiac Disease Dual Antigen Screen Image: 19 Units or less Negative - No significant level of detectable IgA or IgG antibodies against human tissue transglutaminase or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Image: 19 Units or less Negative usch as celiac disease and dermatifis experiments. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Image: 19 Units or less Negative 20.30 Units Negative 20.30 Units 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: 19 Units or less Negative 20.30 Units Negative 20.30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: 19 Units or greater Negative 20.30 Units Negative 20.30 Units 0097709 Tissue Transglutaminase (ITG) Antibody, IgA Image: 10 Umits or greater Negative 4.10 Umits Negative 4.10 Umits 0050736 Endomysial Antibody, IgA bi IFA Less than 1:10 Negative 4.10 Umits Negative 1.10 or less 0056009 Tissue Transglutaminae Antibody, IgG Less than 1:10 Negative Negative	0050340	Immunoglobulin A	Effective February 16, 2021	
0051689 Celiac Dicease Dual Antigen Screen Puris or Jess Postive Postive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DCP) Antibody, IgA Positive or Jess Positive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase or gliadin peptide, suggests possibility of errain gluten ensistive enteropatiles such as celiac disease and dermatifis herpetiformis. 0051357 Deamidated Gliadin Peptide (DCP) Antibody, IgA Positive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase or gliadin peptide; suggests possibility of errain gluten ensistive enteropatiles such as celiac disease and dermatifis herpetiformis. Postive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase of gliadin peptide; suggests possibility of errain gluten ensistive enteropatiles such as celiac disease and dermatifis herpetiformis. Postive - Postive enteropatiles Postive - Postive /ul>			0-2 years: 2-126 mg/dL	
051689 Celiac Disease Dual Antigen Screen 19 Units or less Negative - No significant level of detectable IgA or IgG antibodies against human tissue transglutaninase or gliadin pertide. 0051689 Celiac Disease Dual Antigen Screen 19 Units or less Negative - No significant level of detectable IgA or IgG antibodies against human tissue transglutaninase or gliadin pertide. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA 19 Units or less Negative 20-30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 20-30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or greater Negative 20-30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or greater Negative 20-30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or greater Negative 20-30 Units 0050700 Tissue Transglutaminase (ITG) Antibody, IgA 10 UmL or less Negative 4-10 UmL 11 UmL or greater 0050706 Endomysial Antibody, IgA by IFA Less than 1:10 100 Negative 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 10 Units or greater Negative			3-4 years: 14-212 mg/dL	
0051689 Celiac Disease Dual Antigen Screen Image: Celiac Disease Dual Antigen Screen Image: Celiac Disease Dual Antigen Screen Image: Celiac Disease Dual Provide 0051689 Celiac Disease Dual Antigen Screen Image: Provide Dual Provide Image: Provide Dual Positive - Prosence of IgA and/or IgA an			5-9 years: 52-226 mg/dL	
0051689 Celiac Disease Dual Antigen Screen Image: Celiac Disease Dual Antigen Screen Image: Negative - No significant level of detectable lgA or IgG antbodies against human tisse transglutaminase or gliadin peptide. 0051387 Deamidated Gliadin Peptide (DGP) Antibody, IgA Image: Perturbative enteropathies 20 Units or greater Negative - No significant level of detectable lgA or IgG antbodies against human tisse transglutaminase and rog gliadin peptide: suggests possibility of certain gluton sensitive enteropathies such as celiac disease and dermatitis herpetiformis. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: Perturbative enteropathies 31 Units or greater Negative Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: Perturbative enteropathies 31 Units or greater Negative Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: Perturbative enteropathies 31 Units or greater Negative Positive 0097709 Tissue Transglutaminase (TG) Antibody, IgA Image: Perturbative enteropathies 4.10 Umit Negative Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 Megative Positive Positive 0050736 Endomysial Antibody, IgA Less than 1:10 SumL or less Negative 0050736 Endomysial Antibody, IgA Less than 1:10 SumL or less Negative			10-14 years: 42-345 mg/dL	
0051689 Celiac Disease Dual Antigen Screen 19 Units or less Negative - No significant level of detectable [26 or 1gG antibodies against human tissue transglutaminase or gliadin peptide. 20 Units or greater 19 Units or greater Positive - Presence of IgA antibodies against human tissue transglutaminase or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA 19 Units or less Negative 20:30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 20:30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 20:30 Units 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 20:30 Units 0097709 Tissue Transglutaminase (TG) Antibody, IgA 13 Units or greater Positive 0097706 Tissue Transglutaminase (TG) Antibody, IgA 3 Units or greater Negative 4-10 U/mL Negative 4-10 U/mL 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 Negative 5 U/mL or less Negative 0050736 Tissue Transglutaminase Antibody, IgG Less than 1:10 Negative Negative			15-18 years: 60-349 mg/dL	
O051689 Celiac Disease Dual Antigen Screen I9 Units or less Negative - No significant level of detectable IgA or IgG antibodies against human tissue transplutaminase or gliadin peptide. 20 Units or greater Positive - Presence of IgA antibodies against human tissue transplutaminase and/or gliadin peptide: suggests possibility of certain gluten sensitive enteropathies such as celiac disease and dermatitis herpetiformis. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA I9 Units or less Negative 19 Units or greater I9 Units or greater Negative 20-30 Units Negative Negative 20-30 Units Weak Positive Negative 19 Units or greater Positive Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Inits or greater Negative 0097709 Tissue Transglutaminase (ITG) Antibody, IgA I9 Units or greater Negative 0050736 Endomysial Antibody, IgA by IFA IUmit or greater Negative 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10			19 years and older: 68-408 hig/dL	
0051669 Centre Discuse Dual Antigen Screen 19 Units or less 19 Units or greater Positive - No significant level of detectable IgA or IgG antibodies against human tissue transglutaminase or gliadin peptide. 20 Units or greater Positive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase and/or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Intervention of the set of the se	0051690	Calia a Diagona Dugl		
19 Units or less 19 Units or less Negative - No significant level of decretable igA or igG 20 Units or greater Positive - Presence of IgA and/or IgA antibodies against human issue transglutaminase or gliadin peptide. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Image: IgA or igA antibodies against human issue transglutaminase or gliadin peptide. 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: IgA or igA antibodies against human issue transglutaminase or gliadin peptide. 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: IgA or igA antibodies against human issue transglutaminase (TG) Antibody, IgG 0097709 Tissue Transglutaminase (TG) Antibody, IgA Image: IgA or igA antibodies against human issue	0031089	Antigen Screen		
20 Units or greater Positive - Presence of IgA and/or IgA antibodies against human tissue transglutaminase and/or gliadin peptide: suggests possibility of certrain gluten ensitive enterpathies such as celiac disease and dermatitis herpetiformis. 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA I		Thingen Sereen	19 Units or less	Negative - No significant level of detectable IgA or IgG antibodies against human tissue transglutaminase or gliadin peptide.
0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Inits or less Negative 0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA I9 Units or less Negative 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG I9 Units or less Negative 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG I9 Units or less Negative 10 Units Weak Positive I9 Units or less Negative 20-30 Units Weak Positive I9 Units or less Negative 10 Units or greater Positive I9 Units or less Negative 10 Units or greater Positive I9 Units or less Negative 10 Units or greater Positive I9 Units or greater Positive 0097709 Tissue Transglutaminase (ITG) Antibody, IgA I I10 U/mL 4-10 U/mL 11 U/mL or greater Negative I10 U/mL 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 Kegative I2A by IFA Iess than 1:10 0050609 Tissue Transglutaminase Antibody, IgG IumL or less Negative			20 Units or greater	Positive - Presence of IgA and/or IgA antibodies against
0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA Image: Im				human tissue transglutaminase and/or gliadin peptide;
0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA 19 Units or less Negative 19 Units or less 19 Units or less Weak Positive 20-30 Units Weak Positive 31 Units or greater Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 0050736 Tissue Transglutaminase (TG) Antibody, IgA 3 U/mL or less Negative 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 Weak Positive 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 S U/mL or less				suggests possibility of certain gluten sensitive enteropathies
0051357 Deamidated Gliadin Peptide (DGP) Antibody, IgA I 19 Units or less Negative 20-30 Units Weak Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG I 19 Units or greater Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG I 19 Units or less Negative 20-30 Units Weak Positive 0097709 Tissue Transglutaminase (TG) Antibody, IgA I 3 U/mL or less Negative 4-10 U/mL Weak Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 5 U/mL or less Negative				such as celiac disease and dermatitis herpetiformis.
0051337 Deamidated Oldalin Peptide (DGP) Antibody, IgA 19 Units or less Negative 19 Units or greater Positive Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 19 Units or less Negative Positive 20-30 Units Negative Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG 19 Units or less Negative 19 Units or greater Positive Positive 20-30 Units Weak Positive Positive 30 Units or greater Positive Positive 0097709 Tissue Transglutaminase (rTG) Antibody, IgA 3 U/mL or less Negative 4-10 U/mL Weak Positive Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 5 U/mL or less Negative	0051257	Deemideted Gliedin		
IgA 19 Units or less Negative 20-30 Units Weak Positive 31 Units or greater Positive 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Image: Comparison of the sector o	0051557	Pentide (DGP) Antibody		
Image:		IgA		
Description Description 0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Positive 19 Units or greater Positive 20-30 Units Negative 20-30 Units Weak Positive 19 Units or less Negative 20-30 Units Weak Positive 31 Units or greater Positive 0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: Comparison of the second sec		0	19 Units or less	Negative
Image: Constraint of the second se			20-30 Units	Weak Positive
0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG Interview 19 Units or less Negative 20-30 Units Weak Positive 31 Units or greater Positive 0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: I			31 Units or greater	Positive
0051359 Deamidated Gliadin Peptide (DGP) Antibody, IgG I9 Units or less Negative 19 Units or less 19 Units or less Weak Positive 20-30 Units Weak Positive 31 Units or greater Positive 0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: Comparison of the section of th				
Peptide (DGP) Antibody, IgG Peptide (DGP) Antibody, 20-30 Units Negative 20-30 Units Weak Positive 31 Units or greater Positive 0097709 Tissue Transglutaminase (tTG) Antibody, IgA	0051359	Deamidated Gliadin		
19 Units or less Negative 20-30 Units Weak Positive 31 Units or greater Positive 0097709 Tissue Transglutaminase (tTG) Antibody, IgA		Peptide (DGP) Antibody,		
0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: Construction of Construc		150	19 Units or less	Negative
0097709 Tissue Transglutaminase (tTG) Antibody, IgA Inclar Positive 0050736 Endomysial Antibody, IgA by IFA Inclar Positive 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 5 U/mL or less Negative			20-30 Units	Weak Positive
0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: Construction of greater 3 U/mL or less Negative 4-10 U/mL Weak Positive 11 U/mL or greater Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG 5 U/mL or less Negative			31 Units or greater	Positive
0097709 Tissue Transglutaminase (tTG) Antibody, IgA Image: state			51 Onits of greater	Toshive
3 U/mL or less Negative 4-10 U/mL Weak Positive 11 U/mL or greater Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 5 U/mL or less Negative	0097709	Tissue Transglutaminase (tTG) Antibody, IgA		
4-10 U/mL Weak Positive 11 U/mL or greater Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG 5 U/mL or less			3 U/mL or less	Negative
Image: matrix of the system Image: matrix of the system Positive 0050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG Less than 1:10 5 U/mL or less Negative			4-10 U/mL	Weak Positive
O050736 Endomysial Antibody, IgA by IFA Less than 1:10 0056009 Tissue Transglutaminase Antibody, IgG			11 U/mL or greater	Positive
IgA by IFA 0056009 Tissue Transglutaminase Antibody, IgG 5 U/mL or less Negative	0050736	Endomysial Antibody,	Less than 1:10	
Antibody, IgG 5 U/mL or less Negative	0056000	IgA 0y IFA		
5 U/mL or less Negative	0036009	Antibody, IgG		
			5 U/mL or less	Negative
6-9 U/mL Weak Positive			6-9 U/mL	Weak Positive
10 U/mL or greater Positive			10 U/mL or greater	Positive



New Test Available Now Click for Pricing	<u>3003423</u>	Chymotrypsin by Ir	nmunohistochemistry		СНУМО ІНС
Methodology: Performed: Reported:	Immunohistocher Mon-Fri 1-3 days	nistry			
Specimen Required:	<u>Collect:</u> Tissue. <u>Specimen Prepara</u> cellblock). Protec sections), positive through eSupply not oven bake. <u>Storage/Transport</u> <u>Unacceptable Coi</u> <u>Stability (collection</u>	tion: Formalin fix (10 percent t paraffin block and/or slides f ly charged slides in a tissue tr using ARUP Connect or contact <u>Temperature:</u> Room temperate <u>aditions:</u> Specimens submitted on to initiation of testing): Am	neutral buffered formalin) and p rom excessive heat. Transport tis ansport kit (recommended but no ct ARUP Client Services at (800) ture. Also acceptable: Refrigerate with non-representative tissue ty bient: Indefinitely; Refrigerated:	araffin embed specimen (cells sue block or 5 unstained (3- to t required). ARUP supply #478 522-2787. (Min: 2 slides) If s ed. Ship in cooled container du pe. Depleted specimens. Indefinitely; Frozen: Unaccep	must be prepared into a > 5-micron thick 808 available online sending precut slides, do ring summer months. table
Interpretive Data:					
This test was develop Drug Administration.	ed and its perform This test was perf	ance characteristics determined or a CLIA certified labor	d by ARUP Laboratories. It has not	ot been cleared or approved by l purposes.	y the US Food and

Note: This test is performed as a stain and return (technical) service only.

CPT Code(s): 88342

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

<u>0051720</u>	Complement Factor B	COMP FAC B
Performed:	Monday	
Reported:	10-14 days	

U COP RAND

2011480 **Copper, Random Urine**

Reference Interval:

Effective February 16, 2021

Components	Reference Interval	
Copper, Urine	Less than or equal to 3.2 µg/dL	
Copper Urine - ratio to CRT	10.0-45.0 µg/gCRT	



<u>0020461</u> Copper, Urine

COPPER U

Reference Interval:

Effective February 16, 2021

Test Number	Components	Reference Interv	al	
	Copper, Urine-per volume	Less than or equal to 3.2 µg/dL		
	Copper, Urine-per 24h	3.0-45.0 µg/d		
	Creatinine, Urine - per 24h			
		Age	Male	Female
		3-8 years	140-700 mg/d	140-700 mg/d
		9-12 years	300-1300 mg/d	300-1300 mg/d
		13-17 years	500-2300 mg/d	400-1600 mg/d
		18-50 years	1000-2500 mg/d	700-1600 mg/d
		51-80 years	800-2100 mg/d	500-1400 mg/d
		81 years and older	600-2000 mg/d	400-1300 mg/d
	Copper, Urine-ratio to CRT	10.0-45.0 µg/gCRT		

0060046 Cryptosporidium and Coccidia Exam, Fecal

PARAST

Methodology: Qualitative Concentration/Stain/Microscopy

Note: *Cryptosporidium* antigen detection by EIA is also available for stool samples only. Refer to *Cryptosporidium* Antigen by EIA (0060045). Nucleic Acid Amplification Testing (NAAT) for *Cryptosporidium* and *Cyclospora* also available.

CPT Code(s): 87177; 87207



New Test	<u>3003259</u>	Cytokine Panel 13, CSF	CYT13 CSF
Click for Pricing			

Methodology:	Quantitative Multiplex Bead Assay
Performed:	Sun-Sat
Reported:	1-4 days

Specimen Required: Collect: CSF.

<u>Specimen Preparation:</u> Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.4 mL) <u>Storage/Transport Temperature:</u> **CRITICAL FROZEN. Additional specimens must be submitted when multiple tests are ordered. Ship in an ARUP Standard Transport Tube.** <u>Unacceptable Conditions:</u> Refrigerated specimens. Contaminated or heat inactivated specimens. <u>Stability (collection to initiation of testing)</u>: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 month

Reference Interval:

Test Number	Components	Reference Interval
3003261	Interleukin 2 Receptor, Soluble, CSF	26.8 pg/mL or less
	Interleukin 12, CSF	1.9 pg/mL or less
	Interferon gamma, CSF	4.2 pg/mL or less
	Interleukin 4, CSF	5.2 pg/mL or less
	Interleukin 5, CSF	2.1 pg/mL or less
	Interleukin 10, CSF	12.7 pg/mL or less
	Interleukin 13, CSF	7.3 pg/mL or less
	Interleukin 1 beta, CSF	6.5 pg/mL or less
3003260	Interleukin 6, CSF	7.5 pg/mL or less
	Interleukin 8, CSF	4.6 - 283.5 pg/mL
	Tumor Necrosis Factor - alpha, CSF	1.7 pg/mL or less
	Interleukin 2, CSF	2.1 pg/mL or less
	Interleukin 17, CSF	4.6 pg/mL or less

Interpretive Data:

Results are used to understand the pathophysiology of immune, infectious, or inflammatory disorders, or may be used for research purposes.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.

CPT Code(s): 83520 x13

New York DOH approval pending. Call for status update.



New Test	<u>3003144</u>	Deletion/Duplication Analysis by MLPA	DELDUP
Click for Pricing			
Methodology:	Multiplex Ligatio	m-dependent Probe Amplification	
Performed:	Sun- Sat	I I I I I I I I I I I I I I I I I I I	
Reported:	Within 14 days		
Spacimon Paquirad	Collect: Contact	A DLID's gapatic councelor at (200) 242 2727 autoncian 2141 prior to test subn	nission Disease specific patient

pecimen Required: <u>Collect:</u> Contact ARUP's genetic counselor at (800) 242-2787 extension 2141 prior to test submission. Disease-specific patient history forms are available at www.aruplab.com/Testing-Information/consentforms-patienthistory.jsp <u>Remarks:</u> Submission of a completed patient history form is required. If testing is ordered to assess for a large deletion/duplication previously identified in a family member, submission of the family member's laboratory report is required. Testing will begin once all required documentation is received.

Interpretive Data:

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note:

Deletion/duplication analysis by MLPA is offered for the following genes: *ABCD1, ACADVL, ACVRL1, APC, ATP7A, BMPR1A, BRCA1, BRCA2, CFTR, COL4A5, ENG, F8, F9, FBN1, HBB, MECP2, MEN1, MLH1/MSH2, MSH6, NF1, OTC, PKD1, PKD2, PLOD1, PMS2, PRSS1, PTEN, RASA1, SDHB, SDHC, SDHD, SLC22A5, SHOX, SMAD4, SPINK1, SPRED1, STK11, TP53, VHL.*

Suspected deletions or duplications in exons 12-15 of PMS2, require additional sequencing to exclude pseudogene copy number variants. Additional charges apply.

CPT Code(s): CPT codes vary based on gene.

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

2002693 Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using *Crithidia luciliae*)

Specimen Required: Collect: Serum separator tube.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Plasma. <u>Cerebral spinal fluid</u>. Contaminated, hemolyzed, or severely lipemic specimens. <u>Stability (collection to initiation of testing)</u>: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

0051626 Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgA

EBV A

DNA IFA

Reference Interval: Effective February 16, 2021

Reference Interval			
0.7 U/L or less	Not Detected		
0.8-1.2 U/L	Indeterminate – Repeat testing in 10-14 days may be helpful.		
1.3 U/L or greater	Detected		

HOTLINE NOTE: There is a unit of measure change associated with this test.

Change the unit of measure for component 0051626, EBV Antibody To Viral Capsid Antigen IgA from U/mL to U/L.



0051627 Epste

Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgG and IgA

EBV PAN 3

Reference Interval:

Test Number	Components	Reference Interval			
0050235	Epstein-Barr Virus	Effective February 19, 2013			
	Antibody to Viral Capsid				
	Antigen, IgG	17.9 U/mL or less: Not Detected			
		18.0-21.9 U/mL: Indeterminate. Repeat testing in 10-14 days may be helpful.			
		22.0 U/mL or greater: Detected			
0051626	Epstein-Barr Virus	Effective February 16, 2021			
	Antibody to Viral Capsid				
	Antigen, IgA	0.7 U/L or less: Not Detected			
		0.8 - 1.2 U/L: Indeterminate. Repeat testing in 10-14 days may be helpful.			
		1.3 U/L or greater: Detected			

HOTLINE NOTE: There is a unit of measure change associated with this test.

Change the unit of measure for component 0051626, Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgA from U/mL to U/L.



			,	,
New Test Available Now Click for Pricing	<u>3002737</u>	FISH, Interphase, CD138+ Cells		FISHICD138
Ō.	Fime Sensitive			Oncology Test Request Form Recommended (ARUP form #43099)
	Additional Techi	nical Information		
Methodology: Performed: Reported:	Fluorescence in sit Sun-Sat 3-10 days	u Hybridization		
Specimen Required	: <u>Collect:</u> Non-dilute (Sodium Heparin). <u>Specimen Preparat</u> mL) <u>Storage/Transport</u> <u>Remarks:</u> Desired and diagnosis are <u>Unacceptable Con</u> Stability (collection	ed bone marrow aspirate collected in a heparini <u>ion:</u> Transfer 3 mL bone marrow to a green (so <u>Temperature:</u> Room temperature. FISH probe and pertinent clinical diagnosis rec provided ; absence of this information will del <u>ditions:</u> Paraffin-embedded specimens. Clotted n to initiation of testing): Ambient: 48 hours: R	zed syrin dium he juired wi ay turna specime efrigerat	nge. Also acceptable: Whole blood collected in Green parin) (Min: 1 mL). OR transport 5 mL whole blood (Min: 2 th test order. Testing will not be performed until probe round time. ms. ted: 48 hours; Frozen: Unacceptable

Reference Interval: By report

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: Fluorescence in situ hybridization (FISH) is performed on CD138+ sorted cells (assuming specimen is sufficient for sorting) for multiple myeloma prognosis-specific genomic abnormalities. The comprehensive multiple myeloma panel is available under mnemonic FISHMMP (3002063). The following probes may be ordered individually or in any combination: 1q (*CKS1B*) gain/amplification/17p (*TP53*) loss/deletion, t(4;14) (*IGH/FGFR3* and *MMSET* fusion), 8q (*MYC*) break apart, t(8;14) (*IGH/MYC* fusion), +9/9q (*ASS1*) trisomy/gain, t(11;14) (*IGH/CCND1* fusion and/or +11), 13q (D13S319) deletion, 14q (*IGH*) break apart, t(14;16) (*IGH/MAF* fusion), t(14;20) (*IGH/MAFB* fusion), +15/15q,+17/17q (*PML/RARA* gain).

When this test is ordered in conjunction with a chromosome analysis, specimen prioritization will be given to FISH for the sorting of CD138+ cells. This could impact the successful completion of the chromosome analysis.

If sorting fails to yield sufficient CD138+ cells, testing will be performed using unsorted cells, if available.

If more than one probe is ordered, additional charges will apply.

Contact ARUP Genetics Processing (extension 3301) to add a probe to a current specimen.

Other specimen types may be acceptable, contact Genetics Processing (extension 3301) for specific specimen collection and transportation instructions. ** other sample types acceptable (if reported **without disclaimer** should be added to the OMS build, but not viewable in WOE/CONNECT.

This test must be ordered using Oncology test request form #43099 or through your ARUP interface.

CPT Code(s): 88271; 88275; 88291

New York DOH Approved.



0099906 Fluphenazine

Specimen Required: Patient Prep: Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.

Collect: Plain red. Also acceptable: Lavender (K₂ or K₃EDTA) or pink (K₂ EDTA).

Specimen Preparation: Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Whole blood. Hemolyzed specimens. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)

Reference Interval:

Effective February 16, 2021

Therapeutic Range:	1.0-10.0 ng/mL	
Toxic:	Greater than 15 ng/mL	

Interpretive Data:

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include extrapyramidal symptoms, seizures and neuroleptic malignant syndrome.

See Compliance Statement B: www.aruplab.com/CS

Reference Interval:

silective February 16, 2021				
Therapeutic Range:	5.0-20.0 ng/mL			
Toxic:	Greater than 50 ng/mL			

FLUPHEN



0025055

Heavy Metals Panel 6, Urine with Reflex to Arsenic Fractionated

HYMET 6

Reference Interval:

Test Number	Components	Reference Interval		
0025000	Arsenic, Urine with Reflex to Fractionated	Effective November 13, 2017		
		Test Number	Components	Reference Interval
			Arsenic, Urine - per volume	0-34.9 µg/L (based on Biological Exposure Index)
			Arsenic, Urine - per 24h	0-49.9 µg/d
			Arsenic, Urine-Ratio to CRT	0.0-29.9 µg/gCRT
		0020734	Arsenic, Fractionated, Urine	Refer to report
			Creatinine, Urine - per 24h	Refer to report
0025040	Cadmium, Urine	Effective Novemb	per 13, 2017	
		Test Number	Components	Reference Interval
			Cadmium, Urine - per volume	0.0-1.0 µg/L
			Cadmium, Urine - per 24h	0.0-3.2 μg/d
			Cadmium, Urine - ratio to CRT	0.0-3.2 µg/g crt
			Creatinine, Urine - per 24h	Refer to report
0020461	Copper, Urine	Effective Februar	y 16, 2021	
		Test Number	Components	Reference Interval
			Copper, Urine-per volume	Less than or equal to 3.2 µg/dL
			Copper, Urine-per 24h	3.0-45.0 µg/d
			Creatinine, Urine - per 24h	Refer to report
			Copper, Urine-ratio to CRT	10.0-45.0 µg/gCRT
0025060	Lead, Urine	Effective Novemb	per 12,2018	
		Test Number	Components	Reference Interval
			Lead, Urine - per 24h	0.0-8.1 µg/d
			Lead, Urine - per volume	0.0-5.0 μg/L
			Lead Urine-ratio to CRT	0.0-5.0 ug/gCRT
			Creatinine, Urine - per 24h	Refer to report
0025050	Mercury, Urine	Effective Novemb	per 12,2018	
		Test Number	Components	Reference Interval
			Mercury Urine - per 24h	0.0-20.0 ug/d
			Mercury, Urine - per volume	0.0-5.0 µg/L
			Mercury, Urine - ratio to	0.0-20.0 µg/gCRT
			CRT	
			Creatinine, Urine - per 24h	Refer to report
0020462	Zinc, Urine	Effective Novemb	per 13,2017	
		Test Number	Components	Reference Interval
			Zinc, Urine	15.0-120.0 μg/dL
			Zinc, Urine-per 24h	150.0-1200.0 µg/d
			Zinc, Urine-ratio to CRT	110.0-750.0 µg/gCRT
1	1		Creatinine, Urine - per 24h	Refer to report

2005792

Hemoglobin Evaluation Reflexive Cascade

HOTLINE NOTE: There is a component change associated with this test. Add component 3003512, Gamma Globin (HBG1 and HBG2) Sequencing Remove component 2005804, Hemoglobin Lepore (HBD/HBB) 3 Mutations There is also a reflexive pattern change associated with this test. Add reflex to 3003509, Gamma Globin (HBG1 and HBG2) Seq Bill Remove reflex from 2005838, Hemoglobin Lepore (HBD/HBB) 3 Mut Bill HB CASCADE



New Test3002989Hepatitis Panel, Acute with Reflex to HBsAg Confirmation andHEPACUTEQRReflex to HCV by Quantitative NAAT

Click for Pricing

Methodology:	Qualitative Chemiluminescent Immunoassay/Quantitative Transcription Mediated Amplification
Performed:	Sun-Sat
Reported:	1-2 days
	If reflexed, add 1-3 days

 Specimen Required:
 Collect: Serum separator tube (SST) or Pink (K2EDTA).

 Specimen Preparation:
 Separate serum from cells ASAP or within 2 hours of collection. Transfer 3 mL serum to an ARUP Standard Transport Tube. (Min: 2.0 mL) Also acceptable: K2EDTA plasma.

 Storage/Transport Temperature:
 Frozen.

 Unacceptable Conditions:
 Heparinized plasma. Specimens containing particulate material. Heat-inactivated, severely hemolyzed, or lipemic specimens.

 Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: 2 months (avoid freeze/thaw cycles)

Reference Interval:

Test Number	Components	Reference Inte	erval			
0020093	Hepatitis A Virus Antibody, IgM	Negative				
0020092	Hepatitis B Virus Core Antibody, IgM	Negative	Negative			
0020089	Hepatitis B Virus Surface					
	Antigen with Reflex to	Test Number	Components	Reference Interval		
	Confirmation		Hepatitis B Virus Surface Antigen	Negative		
		0020128	Hepatitis B Virus Surface Antigen, Confirmation	Refer to report		
2010784	Hepatitis C Virus Ab					
	w/Rflx to HCV NAAT		Components	Reference Interval		
		2002483	Hepatitis C Virus Antibody by CIA	Negative		
			Hepatitis C Antibody by CIA Index	0.79 IV or less	Negative	
				0.80 to 0.99 IV	Equivocal	
				1.00 to 10.99 IV	Low Positive	
				11.00 IV or greater	High Positive	
		3000572	Hepatitis C Virus (HCV) by Quantitative NAAT	Not Detected		

Interpretive Data:

This panel of tests should not be used for blood donor screening, associated reentry protocols, or for screening human cell, tissues, and cellular and tissue-based products (HCT/P).

Note: Order this panel when the patient has had clinical acute hepatitis of unknown origin for less than six months. If results for HBsAg are repeatedly reactive with an index value between 1.00 and 50.00, then HBsAg Confirmation will be added. Additional charges apply. If the anti-HCV screening result is low positive or high positive, the Hepatitis C Virus by Quantitative NAAT will be added. Additional charges apply.

CPT Code(s): 80074; if reflexed, add 87341, and 87522

New York DOH Approved.



New Test Available Now Click for Pricin	<u>3000894</u>	Hereditary Hemolytic Ar	nemia Cascade	HHACASCADE
	Patient History Hemoglobinop	r for bathy/Thalassemia Testing		Additional Technical Information
	Test not New Laboratory. An accompany spe	York DOH approved at any approved NPL form must ecimen.	Ů	A recent CBC
Methodology:	High Performan Resonance Ener Cytometry, Cyto	ce Liquid Chromatography (HPLC)/E gy Transfer/Sequencing, Spectrophoto chemical Stain, Multiplex Ligation-E	lectrophoresis/RBC ometry, Visual Identi Dependent Probe Amp	Solubility/Polymerase Chain Reaction (PCR)/Fluorescence fication, Quantitative Enzymatic, Quantitative Flow olification
Performed:	Sun-Sat	·		
Reported:	Varies			
Specimen Require	d: <u>Collect:</u> 3 whole <u>Specimen Prepar</u> Connect or conta <u>Storage/Transpo</u> <u>Remarks:</u> Subm <u>Unacceptable Co</u> <u>Stability (collect</u>)	blood Lavender (K ₂ EDTA) or Pink (<u>ration:</u> Transfer specimens using ARU act ARUP Client Services at (800) 52: <u>rt Temperature:</u> Refrigerated. it with Order: Patient history form, is <u>onditions:</u>	K ₂ EDTA) specimens JP kit (ARUP supply 2-2787. ncluding information	and 3-5 peripheral blood smears. # 54388) available online through eSupply using ARUP from a recent CBC, is required for interpretation.

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: The Hereditary Hemolytic Anemia Cascade begins with initial standard tests to detect possible causes of hemolytic anemia. If the results of the initial tests are suggestive of an abnormal or unstable hemoglobin, RBC membrane instability, or an enzyme or protein deficiency; or if the CBC data is suggestive of a hemoglobinopathy, appropriate testing will be performed at an additional charge. Depending on findings, one or more reflex tests may be required in order to provide a clinical interpretation. Tests added may include electrophoresis, solubility testing, mutational analysis, and/or sequencing.

Quantitation of hemoglobin by HPLC or electrophoresis is most definitive in individuals one year and older. If quantitation of hemoglobin was performed before age one, repeat testing is recommended. Abnormal hemoglobin variants may require additional testing, which increases TAT up to 21 days.

CPT Code(s): 84220, 88184, 82955, 83021. Reflex components billed separately. Additional CPT codes may apply, 85555, 81479, 83068, 81269, 81259, 81363, 81364, 81249, 81443, 85660, 83020

New York DOH approval pending. Call for status update.



New Test	<u>3001842</u> Hereditary Mye	eloid Neoplasms Panel, S	Sequencing	HMYE NGS
Click for Pricin	ng			
	Additional Technical Information	전	Patient History for Here Neoplasms	ditary Myeloid
Methodology:	Massively Parallel Sequencing			
Reported:	Varies 3-6 weeks			
Specimen Require	ed: <u>Collect:</u> Cultured skin fibroblasts (preferre Whole blood: Lavender (EDTA) or yellow Skin punch biopsy: Thaw media prior to t culture transport medium (ARUP Supply # media is not available, collect in plain RPI <u>Specimen Preparation:</u> Cultured skin fibro cultures must be maintained at the client's Skin punch biopsy DO NOT FREEZE. Do with tissue transport medium. Whole blood: Transport 3 mL whole blood <u>Storage/Transport Temperature</u> : Cultured due to lability of cells Skin punch biopsy: Room temperature Whole Blood: Refrigerated. <u>Remarks:</u> Cultured skin fibroblast backup biopsies can be cultured at ARUP at an ad <u>Unacceptable Conditions:</u> Grossly hemoly <u>Stability (collection to initiation of testing</u> Cultured skin fibroblasts: Ambient: 48 hours; Ref Whole blood: Ambient: 72 hours; Refriger	ed) or v (ACD Solution A or B). or issue inoculation. Place skin pur #32788). Available online throug MI, Hanks solution, sterile saline blasts: 2 T-25 flasks at 80 perce institution until testing is compl o not place in formalin. Transpor d. (Min: 1.5 mL) skin fibroblasts: Critical room te cultures must be retained at the ditional charge. rzed or frozen specimens; formal <u>b</u> ars; Refrigerated: Unacceptable; efrigerated: 48 hours; Frozen: Un rated: 1 week; Frozen: Unaccept	nch biopsy in a sterile, screw-top gh eSupply using ARUP Connec e, or ringers. int confluency, Fill flasks with cu lete. rt a 4 mm skin biopsy in a sterile emperature. Must be received wi client's institution until testing is lin fixed tissue, FFPE Frozen: Unacceptable, nacceptable table	container filled with tissue t. If cytogenetics tissue ulture media. Backup , screw-top container filled thin 48 hours of shipment complete. Skin punch

Reference Interval: By report

Interpretive Data:

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Genes tested: ANKRD26*, ATM, BLM, CBL, CEBPA, DDX41, ELANE, ETV6, GATA1, GATA2, KRAS, NBN, PTPN11*, RUNX1, SAMD9, SAMD9L, SRP72*, TERC, TERT, TP53.

If a skin punch biopsy is submitted, specimen will be reflexed for culturing. Additional charge apply.

CPT Code(s): 81479; for skin punch biopsy, add 88233.

New York DOH approval pending. Call for status update.



0092283 Herpes Gestationis Factor (Complement-Fixing Basement Membrane Zone Antibody IgG)

HG FACTOR

Specimen Required: Collect: Plain red or serum separator tube (SST).

<u>Specimen Preparation:</u> Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL) <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Hemolyzed or lipemic specimens. <u>Stability (collection to initiation of testing):</u> Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely

Note: The methodology is indirect immunofluorescence (IFA) of serum on human split skin substrate for detection of complement-fixing (herpes gestationis factor) and non-complement-fixing IgG basement membrane zone antibodies. For specimens less than 1 mL, call the Immunodermatology Laboratory at (866) 266-5699.



0050980 Humoral Immunity Panel I

HUMPAN I

Methodology: Quantitative Immunoturbidimetry/Semi-Quantitative Multiplex Bead Assay

Specimen Required: Collect: Serum separator tube.

<u>Specimen Preparation:</u> Separate serum from cells ASAP or within 2 hours of collection. Transfer 5.5 mL serum to ARUP Standard Transport Tubes. (Min: 2.5 mL total) <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Plasma. <u>Stability (collection to initiation of testing):</u> After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months (avoid repeated freeze/thaw cycles). (Refer to individual components for further information.)

Reference Interval:

Test Number	Components	Reference Interval
0050210	Diphtheria Antibody, IgG	Antibody concentration of > 0.1 IU/mL is usually considered protective.
0050535	Tetanus Antibody, IgG	Antibody concentration of > 0.1 IU/mL is usually considered protective.
0050725	Streptococcus pneumoniae Antibodies, IgG (14 Serotypes)	
0050340	Immunoglobulin A	Effective February 16, 2021
		0-2 years: 2-126 mg/dL
		3-4 years: 14-212 mg/dL
		5-9 years: 52-226 mg/dL
		10-14 years: 42-345 mg/dL
		15-18 years: 60-349 mg/dL
		19 years and older: 68-408 mg/dL
0050350	Immunoglobulin G	Effective February 16, 2021
		0-2 years: 242-1108 mg/dL
		3-4 years: 485-1160 mg/dL
		5-9 years: 514-16/2 mg/dL
		10-14 years: 301-1032 hig/dL 15-18 years: 470-1433 mg/dL
		19 years and older: 768-1632 mg/dL
0050355	Immunoglobulin M	Effective February 16, 2021
0050555		D 2 merri 21 215 mg/dL
		3.4 years: 26.155 mg/dL
		5-9 years: 26-188 mg/dI
		10-14 years: 47-252 mg/dL
		15-18 years: 26-232 mg/dL
		19 years and older: 35-263 mg/dL
0050571	Immunoglobulin G Subclass 1	Effective February 16, 2021
		0-2 years: 167-900 mg/dL
		3-4 years: 313-941 mg/dL
		5-9 years: 363-1276 mg/dL
		10-14 years: 316-1076 mg/dL
		15-18 years: 325-894 mg/dL 10 years and older: 240 1118 mg/dL
0050572	Immunoglobulin G Subalass 2	Ffractive Echement 16, 2021
0050572	minulogiobulin O Subclass 2	D 2 years: 55 250 mg/dL
		3-4 years: 72-287 mg/dL
		5-9 years: 27-398 mg/dL
		10-14 years: 86-509 mg/dL
		15-18 years: 156-625 mg/dL
		19 years and older: 124-549 mg/dL
0050573	Immunoglobulin G Subclass 3	Effective February 16, 2021
		0-2 years: 34-85 mg/dL
		3-4 years: 25-117 mg/dL
		5-9 years: 17-169 mg/dL
		10-14 years: 14-201 mg/dL
		13-10 years and older: 21-134 mg/dI
0050576	Immunoglobulin G Subclass A	Effective February 16, 2021
0050570	minunogioodini O Subciass 4	0.2 years 1.24 mg/dL
		0-2 years: 1-54 mg/dL 3-4 years: 1-65 mg/dL
		5-9 years: 0-168 mg/dL
		10-14 years: 1-103 mg/dL
		15-18 years: 2-170 mg/dL
		19 years and older: 1-123 mg/dL



New Test	<u>3003486</u>	Immunoglobulin D, Serum	IG D
Click for Pricing	2		
Methodology:	Quantitative Imm	aunoturbidimetry	
Performed:	Mon, Wed, Fri		
Reported:	1-4 days		
Specimen Required	I: Collect: Serum so	eparator tube.	
	Specimen Prepar	ation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL ser	um to an ARUP Standard
	Transport Tube.	(Min: 0.5 mL)	
	Storage/Transpor	<u>et Temperature:</u> Retrigerated.	
	Unacceptable Co	<u>inditions:</u> Grossly nemolyzed or lipemic specimens.	stade 14 days; Frazan: 6
	months	ton to mination of testing): After separation from cens: Anolent: Unacceptable, Kerngera	led: 14 days; Flozen: 6
Reference Interv	al: Less t	than or equal to 15.3 mg/dL	
Interpretive Data IgD is one of the fiv an early B-cell antig	a: e classes of immune en receptor, howev	oglobulin. IgD is mainly found on the surface of B-cells and may help regulate B-cell fur er, the function of the circulating IgD is largely unknown.	nction. IgD likely serves as
CPT Code(s):	82784		
New York DOH Ap	proved.		

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

New Test	<u>3003485</u>	Immunoglobulin G, CSF	IGGCSF
Click for Pricing			

Methodology:	Quantitative Immunoturbidimetry
Performed:	Sun-Sat
Reported:	Within 24 hours

Specimen Required: Collect: CSF.

 <u>Specimen Preparation:</u> Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)
 <u>Storage/Transport Temperature:</u> Refrigerated.
 <u>Unacceptable Conditions:</u> Grossly bloody or hemolyzed specimens.
 <u>Stability (collection to initiation of testing)</u>: Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 6 months

Reference Interval: 0.0-6.0 mg/dL

CPT Code(s): 82784

New York DOH Approved.



0050340 Immunoglobulin A

Methodology: Quantitative Immunoturbidimetry

Specimen Required: <u>Collect:</u> Serum separator tube or green (sodium or lithium heparin).

Specimen Preparation: Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Grossly hemolyzed or lipemic specimens Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

Reference Interval:

Effective February 16, 2021

Age	Reference Interval
0-2 years	2-126 mg/dL
3-4 years	14-212 mg/dL
5-9 years	52-226 mg/dL
10-14 years	42-345 mg/dL
15-18 years	60-349 mg/dL
19 years and older	68-408 mg/dL

0093149 Immunoglobulin A Subclasses (1 and 2)

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: Serum separator tube.

 Specimen Preparation:
 Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.7 mL)

 Storage/Transport Temperature:
 Refrigerated

 Unacceptable Conditions:
 Grossly hemolyzed or lipemic specimens

 Stability (collection to initiation of testing):
 After separation from cells: Ambient:
 Unacceptable; Refrigerated:

 Months
 Stability (collection to initiation of testing):
 After separation from cells:
 Ambient:

Reference Interval: Effective February 16, 2021

Test Number	Components	Reference Interval
0050340	Immunoglobulin A	Effective February 16, 2021
		0-2 years: 2-126 mg/dL
		3-4 years: 14-212 mg/dL
		5-9 years: 52-226 mg/dL
		10-14 years: 42-345 mg/dL
		15-18 years: 60-349 mg/dL
		19 years and older: 68-408 mg/dL
	Immunoglobulin A	0-2 years: 3-145 mg/dL
	Subclass 1	3-4 years: 22-278 mg/dL
		5-9 years: 43-337 mg/dL
		10-14 years: 37-430 mg/dL
		15-18 years: 76-394 mg/dL
		19 years and older: 60-294 mg/dL
	Immunoglobulin A	0-2 years: 1-15 mg/dL
	Subclass 2	3-4 years: 3-44 mg/dL
		5-9 years: 7-56 mg/dL
		10-14 years: 1-109 mg/dL
		15-18 years: 14-54 mg/dL
		19 years and older: 6-61 mg/dL

IGA



0050341 Immunoglobulin A, CSF

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: CSF.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly bloody or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 6 months

0050350 Immunoglobulin G

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: Serum separator tube

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly hemolyzed or lipemic specimens

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

Reference Interval: Effective February 16, 2021

ficence rebrany 10, 2021		
Age	Reference Interval	
0-2 years	242-1108 mg/dL	
3-4 years	485-1160 mg/dL	
5-9 years	514-1672 mg/dL	
10-14 years	581-1652 mg/dL	
15-18 years	479-1433 mg/dL	
19 years and older	768-1632 mg/dL	

0050576 Immunoglobulin G Subclass 4

Methodology:	Quantitative Immunoturbidimetry
Performed:	Sun-Sat
Reported:	1-3 days

Specimen Required: Collect: Serum separator tube.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly hemolyzed or lipemic specimens

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

Reference Interval:

Effective February 16, 2021

Age	Reference Interval
0-2 years	1-34 mg/dL
3-4 years	1-65 mg/dL
5-9 years	0-168 mg/dL
10-14 year	1-103 mg/dL
15-18 years	2-170 mg/dL
19 years and older	1-123 mg/dL

IGA CSF

IGG

IGG4



0050577 Immunoglobulin G Subclasses (1, 2, 3, 4)

Methodology:	Quantitative Immunoturbidimetry
Daufamu al.	0 0 /

Performed:Sun-SatReported:1-3 days

Specimen Required: Collect: Serum separator tube.

<u>Specimen Preparation:</u> Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL) <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Grossly hemolyzed or lipemic specimens

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

IGG SUB

Reference Interval:

Test Number	Components	Reference Interval
0050571	Immunoglobulin G Subclass 1	Effective February 16, 2021 0-2 years: 167-900 mg/dL 3-4 years: 313-941 mg/dL 5-9 years: 363-1276 mg/dL 10-14 years: 316-1076 mg/dL 15-18 years: 325-894 mg/dL 19 years and older: 240-1118 mg/dL
0050572	Immunoglobulin G Subclass 2	Effective February 16, 2021 0-2 years: 55-359 mg/dL 3-4 years: 72-287 mg/dL 5-9 years: 27-398 mg/dL 10-14 years: 86-509 mg/dL 15-18 years: 156-625 mg/dL 19 years and older: 124-549 mg/dL
0050573	Immunoglobulin G Subclass 3	Effective February 16, 2021 0-2 years: 34-85 mg/dL 3-4 years: 25-117 mg/dL 5-9 years: 17-169 mg/dL 10-14 years: 14-201 mg/dL 15-18 years: 34-246 mg/dL 19 years and older: 21-134 mg/dL
0050576	Immunoglobulin G Subclass 4	Effective February 16, 2021 0-2 years: 1-34 mg/dL 3-4 years: 1-65 mg/dL 5-9 years: 0-168 mg/dL 10-14 years: 1-103 mg/dL 15-18 years: 2-170 mg/dL 19 years and older: 1-123 mg/dL

Interpretive Data:

The total IgG (mg/dL) can be derived from the sum of the subclass IgG1, IgG2, IgG3, and IgG4 values. However, a confirmatory and more precise total IgG is available by the immunoturbidimetric method of quantitation for total IgG. Refer to test Immunoglobulin G, Serum (0050350).



0050676 Immunoglobulin G, CSF Index

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: CSF AND serum separator tube. Serum specimen should be drawn within 48 hours of CSF collection.

<u>Specimen Preparation</u>: Centrifuge and separate CSF to remove cellular material. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL CSF **AND** 1 mL serum to individual ARUP Standard Transport Tubes. (Min: 0.5 mL CSF **AND** 0.5 mL serum) <u>Storage/Transport Temperature:</u> Refrigerated.

Unacceptable Conditions: Grossly bloody or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months (if frozen within 24 hours)

Reference Interval:

Test Number	Components	Reference Interval
0050350	Immunoglobulin G	Effective February 16, 2021
		0-2 years: 242-1108 mg/dL
		3-4 years: 485-1160 mg/dL
		5-9 years: 514-1672 mg/dL
		10-14 years: 581-1652 mg/dL
		15-18 years: 479-1433 mg/dL
		19 years or older: 768-1632 mg/dL
3003485	Immunoglobulin G, CSF	0.0-6.0 mg/dL
0050671	Albumin Serum	3500-5200 mg/dL
0050200	Albumin, CSF	0-35 mg/dL
	Albumin Index	0.0-9.0
	CSF IgG Synthesis Rate	Less than or equal to 8.0 mg/d
	IgG Albumin Ratio	0.09-0.25
	IgG Index	0.28-0.66

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 0050671, Albumin by Nephelometry from Albumin by Nephelometry to Albumin Serum.

0050680 Immunoglobulin G/Albumin Ratio, CSF

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: CSF.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly bloody or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 6 months

IGG SYN

IGG/ALB



0050355 Immunoglobulin M

Methodology: Quantitative Immunoturbidimetry

Specimen Required: <u>Collect:</u> Serum separator tube or green (sodium or lithium heparin).

Specimen Preparation: Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Grossly hemolyzed or lipemic specimens. <u>Stability (collection to initiation of testing)</u>: After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

Reference Interval:

Effective February 16, 2021

Age	Reference Interval
0-2 years	21-215 mg/dL
3-4 years	26-155 mg/dL
5-9 years	26-188 mg/dL
10-14 years	47-252 mg/dL
15-18 years	26-232 mg/dL
19 years and older	35-263 mg/dL

0050356 Immunoglobulin M, CSF

Methodology:Quantitative ImmunoturbidimetryPerformed:Wed, SatReported:1-5 days

Specimen Required: Collect: CSF.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly bloody or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

IGM

IGM CSF



0050630 Immunoglobulins (IgA, IgG, IgM), Quantitative

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: Serum separator tube

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.7 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Grossly hemolyzed and lipemic specimens. Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months

Reference Interval:

Test Number	Components	Reference Interval
0050340	Immunoglobulin A	Effective February 16, 2021
		0-2 years: 2-126 mg/dL 3-4 years: 14-212 mg/dL 5-9 years: 52-226 mg/dL 10-14 years: 42-345 mg/dL 15-18 years: 60-349 mg/dL
		19 years and older: 68-408 mg/dL
0050350	Immunoglobulin G	Effective February 16, 2021
		0-2 years: 242-1108 mg/dL 3-4 years: 485-1160 mg/dL 5-9 years: 514-1672 mg/dL 10-14 years: 581-1652 mg/dL 15-18 years: 479-1433 mg/dL 19 years and older: 768-1632
0050355	Immunoglobulin M	Effective February 16, 2021
		0-2 years: 21-215 mg/dL 3-4 years: 26-155 mg/dL 5-9 years: 26-188 mg/dL 10-14 years: 47-252 mg/dL 15-18 years: 26-232 mg/dL 19 years and older: 35-263 mg/dL

0050631 Immunoglobulins, CSF Quantitative

QNTIG CSF

Methodology: Quantitative Immunoturbidimetry

Specimen Required: Collect: CSF.

Specimen Preparation: Centrifuge and separate to remove cellular material. Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.6 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Grossly bloody or hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 month; Frozen: 6 months

Reference Interval:

Test Number	Components	Reference Interval
0050341	Immunoglobulin A, CSF	0.0-0.7 mg/dL
3003485	Immunoglobulin G, CSF	0.0-6.0 mg/dL
0050356	Immunoglobulin M, CSF	0.0-0.7 mg/dL



0070413 Inhibin B

INHIBINB

IL2R CSF

Specimen Required: Patient Prep: For premenopausal females, collection is preferred during the follicular phase of the menstrual cycle.

Collect: Serum separator tube or plain red.

Specimen Preparation: Transport 0.5 mL serum. (Min: 0.2 mL)

Storage/Transport Temperature: Frozen.

Unacceptable Conditions: Room temperature specimens. Grossly hemolyzed specimens. Plasma

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 1 month

Reference Interval:

Effective February 16, 2021

Male	Female
<15 days: 68-373 pg/mL	1 day-12 years: 1-182 pg/mL
15 days-6 months: 42-516 pg/mL	13-41 years (regular cycle, follicular phase): 8-223 pg/mL
7 months-7 years: 24-300 pg/mL	42-51 years (regular cycle, follicular phase): 1-107 pg/mL
8-30 years: 47-383 pg/mL	51-76 years (postmenopausal): 1-11 pg/mL
31-72 years: 10-357 pg/mL	

New Test3003261Interleukin 2 Receptor, Soluble, CSFClick for Pricing

Methodology:Quantitative Multiplex Bead AssayPerformed:Sun-SatReported:1-4 days

Specimen Required: Collect: CSF.

Specimen Preparation: Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.4 mL) Storage/Transport Temperature: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. Ship in an ARUP Standard Transport Tube. Unacceptable Conditions: Refrigerated specimens. Contaminated or heat-inactivated specimens. Stability (collection to initiation of testing): Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 month

Reference Interval: 26.8 pg/mL or less

Interpretive Data:

Results are used to understand the pathophysiology of immune, infectious, or inflammatory disorders, or may be used for research purposes.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.

CPT Code(s): 83520

New York DOH approval pending. Call for status update.



New Test	<u>3003260</u>	Interleukin 6, CSF	IL6 CSF
Click for Pricing			
Methodology:	Quantitative Mult	iplex Bead Assay	
Performed:	Sun-Sat		
Reported:	1-4 days		
Specimen Required	: Collect: CSF.		
	Specimen Prepara	tion: Transfer 1 mL CSF to a	n ARUP Standard Transport Tube. (Min: 0.4 mL)
	Storage/Transport	Temperature: CRITICAL F	ROZEN. Separate specimens must be submitted when multiple tests are ordered.
	Ship in an ARUF	Standard Transport Tube.	
	Unacceptable Cor	nditions: Refrigerated specime	ns. Contaminated or heat-inactivated specimens.
	Stability (collection	on to initiation of testing): An	bient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 month.
Reference Interva	d: 7.5 pg/	/mL or less	
Interpretive Data Results are used to us	: nderstand the patho	physiology of immune, infect	ous, or inflammatory disorders, or may be used for research purposes.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: Cytokine levels may demonstrate diurnal variation. For longitudinal comparison, it is recommended that cytokine levels be determined at the same time of day.

CPT Code(s): 83520

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

New Test	<u>3003506</u>	Kappa/Lambda Light Chain Panel by in situ Hybridization on Paraffin	K/L P ISH
Click for Pricing			
Methodology:	In situ hybridization	n (ISH)	
Performed:	Mon-Fri		
Reported:	2-5 days		
Specimen Required	: Collect: Tissue.		
	Specimen Preparati	on: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue. Transpo	rt tissue block or 10
	unstained 5 micron	slides in a tissue transport kit (ARUP supply #47808). Available online through eSupply us	ing ARUP Connect™

unstained 5 micron slides in a tissue transport kit (ARUP supply #47808). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 5 slides) Protect paraffin block and/or slides from excessive heat. <u>Storage/Transport Temperature:</u> Room temperature or refrigerated. Ship in cooled container during summer months. <u>Remarks:</u> Include surgical pathology report. <u>Unacceptable Conditions:</u> Specimens fixed or processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified or frozen specimens. <u>Stability (collection to initiation of testing):</u> Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Interpretive Data:

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 88368; 88369

New York DOH Approved.



New Test	<u>3003525</u>	Kappa/Lambda Light Chain Panel by In Situ Hybridization	SO KLP ISH
		Stain Only	

Click for Pricing

Methodology:	In situ hybridization (ISH)
Performed:	Mon-Fri
Reported:	2-5 days

Specimen Required: Collect: Tissue or cells.

Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 8 unstained (3- to 5-micron thick sections), positively-charged slides in a tissue transport kit (ARUP supply #47808). Available online through eSupply using ARUP Connect[™] or contact ARUP Client Services at (800) 522-2787. (Min: 4 slides). If sending precut slides, do not oven bake. Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. Remarks: **IMMUNOHISTOCHEMISTRY ORDERING AND SUBMISSION DETAILS:** Submit electronic request. If you do not have electronic ordering capability, use an ARUP Immunohistochemistry Stain Form (#32978) with an ARUP client number. For additional technical details, contact ARUP Client Services at (800) 522-2787. Unacceptable Conditions: Specimens submitted with non-representative tissue type. Depleted specimens. Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 88368; 88369

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

New Test	<u>3003311</u>	Kratom (Mitragynine) - Screen with Reflex to Confirmation/Quantitation, Urine	KRATOM U
Click for Pricin	y ⇒		
Methodology:	Qualitative Imm	unoassay/Quantitative Liquid Chromatography/Tandem Mass Spectrometry	
Performed:	Varies		
Reported:	6-9 days		
Specimen Require	I: Collect: Urine.		
	Specimen Prepa	ration: Transfer 10 mL urine to ARUP Standard Transport Tubes. (Min: 1 mL)	
	Test is not perf	ormed at ARUP; separate specimens must be submitted when multiple tests are ordered.	
	Storage/Transpo	rt Temperature: Frozen. Also acceptable: Refrigerated.	
	Unacceptable Co	onditions: Urine from preservative tube	
	Stability (collect	tion to initiation of testing): Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 6 months	
Reference Interv	al: By re	eport	
Note: If screen is p	ositive, then confir	mation will be added. Additional charges apply.	
CPT Code(s):	80307 if reflexed	d, add 80323	
New York DOH ap	proval pending. Ca	ll for status update.	



<u>0051692</u>	Mannose Binding Lectin	MBL
Specimen Require	 <u>Collect:</u> Serum separator tube, plain red, or green (lithium heparin). <u>Specimen Preparation:</u> Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL s an ARUP Standard Transport Tube. (Min 0.2 mL) <u>Storage/Transport Temperature:</u> CRITICAL FROZEN. Separate specimens must be submitted when multiple Unacceptable Conditions: Specimens collected in EDTA or citrate. Contaminated or heat-inactivated specimens. Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: Una 1 year (avoid repeated freeze/thaw cycles) 	serum or plasma to tests are ordered. acceptable; Frozen:
<u>3000146</u>	Maternal Screening, Sequential, Specimen #1, hCG, PAPP-A, NT	MS SEQ1
HOTLINE NOT Add component 300	E: There is a component change associated with this test. 03440, Donor Egg Age at Harvest	
<u>3000144</u>	Maternal Serum Screen, Alpha Fetoprotein	MS AFP
HOTLINE NOT Add component 300 Add component 300	E: There is a component change associated with this test. 00151, Client Provided In Vitro Fertilization 03440, Donor Egg Age at Harvest	
<u>3000143</u>	Maternal Serum Screen, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (Quad)	MS QUAD
HOTLINE NOT Add component 300	E: There is a component change associated with this test.)3440, Donor Egg Age at Harvest	
<u>3000145</u>	Maternal Serum Screen, First Trimester, hCG, PAPP-A, NT	MS FTS
HOTLINE NOT Add component 300	E: There is a component change associated with this test.)3440, Donor Egg Age at Harvest	
<u>3000147</u>	Maternal Serum Screening, Integrated, Specimen #1, PAPP-A, NT	MS INT1
HOTLINE NOT	E: There is a component change associated with this test.	

Add component 3003440, Donor Egg Age at Harvest



Membranous Nephropathy Comprehensive Autoantibody Panel

Available Now Click for Pricing	
	Additional Technical Information
Methodology:	Semi-Quantitative Indirect Fluorescent Antibody
Performed:	Tue
Reported:	1-8 days
Specimen Required	: <u>Collect:</u> Serum Separator Tube
	Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard
	Transport Tube. (Min: 0.2 mL)
	Storage/Transport Temperature: Refrigerated
	Unacceptable Conditions: Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated
	Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval:

New Test

3003477

201	11828	Phospholipase A2 Receptor (PLA2R) Antibody, IgG with Reflex to Titer	Less than 1:10
300	03480	Antithrombospondin Type-1 Domain-Containing 7A (THSD7A) Antibody, IgG with Reflex to Titer	Less than 1:10

Interpretive Data:

Refer to individual components.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: If Phospholipase A2 Receptor Antibody, IgG is positive, then a Phospholipase Receptor A2 Antibody, IgG titer will be added. Additional charges apply. If THSD7A Antibody, IgG is positive, then a THSD7A Antibody, IgG titer will be added.. Additional charges apply.

CPT Code(s): 86255 x2; if reflexed, add 86256 x2

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

0050184 Metanephrines, Plasma (Free)

META PF

MNCA PAN

Specimen Required: <u>Patient Prep:</u> Drugs and medications may affect results and should be discontinued for at least 72 hours prior to specimen collection, if possible. Collection of the specimen after the patient has rested for 15 minutes in a supine position is recommended.

Collect: Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Specimen Preparation: Centrifuge within 1 hour. Transfer 2 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL) Avoid hemolysis.

Storage/Transport Temperature: Frozen. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions: Plasma separator tubes. Body fluids other than EDTA or heparinized plasma. Non-frozen specimens.

Grossly hemolyzed.

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month



2002715 Monoclonal Protein Study, Expanded Panel, Serum

Specimen Required: Collect: Serum Separator Tube (SST).

<u>Specimen Preparation:</u> Separate from cells ASAP or within 2 hours of collection. Transfer 2.5 mL serum to an ARUP Standard Transport Tube. (Min: 2.0 mL) <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Plasma. Room temperature specimens.

Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 1 month

IFE FLC

Reference Interval:

Test Number	Components	Reference Interval				
0050640	Protein Electrophoresis,	Effective August 1	9, 2019			
	Serum	Test Number	Components	Reference Interval		
			Total Protein, Serum	Refer to report		
			Albumin	Refer to report		
			Alpha-1 Globulins	Refer to report		
			Alpha-2 Globulins	Refer to report		
			Beta Globulins	Refer to report		
			Gamma	Refer to report		
0050340	Immunoglobulin A	Effective February	16, 2021			
		0-2 years: 2-126 m	g/dL			
		3-4 years: 14-212 i	mg/dL			
		5-9 years: 52-226 mg/dL				
		10-14 years: 42-345 mg/dL				
		13-18 years: 00-349 ing/dL 19 years and older: 68-408 mg/dL				
		19 years and older.	. 08-408 mg/dL			
0050350	Immunoglobulin G	Effective February 16, 2021				
		0-2 years: 242-1108 mg/dL				
		3-4 years: 485-1160 mg/dL				
		5-9 years: 514-167	2 mg/dL			
		10-14 years: 581-1652 mg/dL				
		15-18 years: 479-1	433 mg/dL			
	-	19 years and older:	: 768-1632 mg/dL			
0050355	Immunoglobulin M	Effective February	/ 16, 2021			
		0-2 years: 21-215 i	mg/dL			
		3-4 years: 26-155 i	mg/dL			
		5-9 years: 26-188 i	mg/dL			
		10-14 years: 47-25	2 mg/dL			
		15-18 years: 26-23	2 mg/dL			
			10, 2020			
	Light Chains, Serum	3.30 - 19.40 mg/L	18, 2020			
	Lambda Ouantitative Free	Effective February	18, 2020			
	Light Chains, Serum	5.71-26.30 mg/L	-,			
	Kappa/Lambda Free	0.26-1.65				
	Light Chain Ratio, Serum					



2007967 Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis Manual Reflex to Titer and Neuronal Immunoblot

MSNCR

Methodology: Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot/Quantitative Immunofixation Electrophoresis/Quantitative Spectrophotometry

Specimen Required: Collect: Serum Separator Tube (SST).

<u>Specimen Preparation:</u> Separate serum from cells ASAP or within 2 hours of collection. Transfer 5 mL serum to an ARUP Standard Transport Tube. (Min: 2.5 mL) <u>Storage/Transport Temperature:</u> Refrigerated <u>Unacceptable Conditions:</u> Plasma, CSF, or other body fluids. Contaminated, heat-inactivated, grossly hemolyzed, severely icteric, or lipemic specimens.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 1 month

Reference Interval:



Test Number	Components	Reference Interval		
	Albumin	3.75-5.01 g/dL		
	Alpha-1 Globulins	0.19-0.46 g/dL		
	Alpha-2 Globulins	0.48-1.05 g/dL		
	Beta Globulins	0.48-1.10 g/dL		
0050240	Gamma	0.62-1.51 g/dL		
0050340	Immunoglobulin A	Effective February 16, 2021 0-2 years: 2-126 mg/dL 3-4 years: 14-212 mg/dL 5-9 years: 52-226 mg/dL 10-14 years: 42-345 mg/dL 15-18 years: 60-349 mg/dL 19 years and older: 68-408 mg/dL		
0050350	Immunoglobulin G	Effective February 16, 2021		
		0-2 years: 242-1108 mg/dL 3-4 years: 485-1160 mg/dL 5-9 years: 514-1672 mg/dL 10-14 years: 581-1652 mg/dL 15-18 years: 479-1433 mg/dL 19 years and older: 768-1632 mg/dL		
0050355	Immunoglobulin M	Effective February 16, 2021		
		0-2 years: 21-215 mg/dL 3-4 years: 26-155 mg/dL 5-9 years: 26-155 mg/dL 10-14 years: 47-252 mg/dL 15-18 years: 26-232 mg/dL 19 years or older: 35-263 mg/dL		
	Total Protein, Serum	August 19,2019 Refer to Report		
	Asialo-GM1 Antibodies,			
	IgG/IgM	29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GM1 Antibodies,			
	IgG/IgM	29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GD1a Antibodies,			
	IgG/IgM	29 IV or less	Negative	
		30-50 IV	Equivocal	
		101 IV or greater	Strong Positive	
			Buong i Ushive	
	GD1b Antibodies			
	IgG/IgM	29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GQ1b Antibodies,			
	IgG/IgM	29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
0051284	Sulfate-3-Glucuronyl Paragloboside (SGPG) Antibody, IgM	Less than 1.00 IV		
0051285	Myelin Associated Glycoprotein (MAG) Antibody, IgM	Less than 1000 TU		
2007961		Effective August 17, 2020		
		Test Number Components	Reference Interval	



Paraneoplastic Antibodies (PCCA/ANNA) by IFA		Purkinje Cell/Neuronal Nuclear IgG Scrn	None Detected
with Reflex to Titer and Immunoblot		Neuronal Nuclear Antibody (ANNA) IFA Titer, IgG	Less than 1:10
		Purkinje Cell Antibody, Titer	Less than 1:10
	3002917	Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot, Serum	Refer to report



MSN PAN

0051225 Motor Neuropathy Panel

Methodology: Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Immunoturbidimetry/Quantitative Capillary Electrophoresis/Qualitative Immunofixation Electrophoresis/Quantitative Spectrophotometry

Reference Interval:



Test Number	oer Components Reference Interval			
	Asialo-GM1 Antibodies, IgG/IgM			
		29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GM1 Antibodies, IgG/IgM			
		29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GD1a Antibodies, IgG/IgM			
		29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GD1b Antibodies, IgG/IgM			
		29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	GQ1b Antibodies, IgG/IgM			
		29 IV or less	Negative	
		30-50 IV	Equivocal	
		51-100 IV	Positive	
		101 IV or greater	Strong Positive	
	Total Protein, Serum	August 19,2019		
		Refer to Report		
	Albumin	3.75-5.01 g/dL		
	Alpha-1 Globulins	0.19-0.46 g/dL		
	Alpha-2 Globulins	0.48-1.05 g/dL		
	Beta Globulins	0.48-1.10 g/dL		
0050340		Effective February 16, 2021		
0050540	Ininitallogiobanii A	0-2 years: 2-126 mg/dL		
		0-2 years: 2-126 mg/dL 3-4 years: 14-212 mg/dL		
		5-9 years: $52-226$ mg/dL		
		10-14 years: 42-345 mg/dL		
		15-18 years: 60-349 mg/dL		
		19 years and older: 68-408 mg/dL		
0050350	Immunoglobulin G	Effective February 16, 2021		
		0-2 years: 242-1108 mg/dL		
		3-4 years: 485-1160 mg/dL		
		5-9 years: 514-1672 mg/dL		
		10-14 years: 581-1652 mg/dL		
		15-18 years: 4/9-1433 mg/dL	1T	
		19 years and older. 708-1052 hig/c	IL	
0050255	In mun o do hulin M	Effective Echenogy 16, 2021		
0050355	Immunoglobulin M	Effective February 16, 2021		
		0-2 years: 21-215 mg/dL		
		3-4 yaers: 26-155 mg/dL		
		5-9 years: 26-188 mg/dL 10-14 years: 47, 252 mg/dI		
		15-18 years: 26-232 mg/dL		
		19 years and older: 35-263 mg/dL		
		<u> </u>		
0051285	Myelin Associated Glyconrotein (MAG) Antibody JaM	Less than 1000 TU		
0051284	Sulfate-3-Glucuronyl Paragloboside (SGPG) Antibody. IgM	Less than 100 IV		
0001207	Sanate 5 Gracutony 1 augioboside (501 0) Antibody, IgW	2000 than 1.00 IV		



3003566 **New Test** Mucopolysaccharidoses Type 1/2, Total Heparan Sulfate and NRE **MPS 1/2 SP** (Sensi-Pro®) Quantitative, Serum or Plasma Available Now **Click for Pricing** Test not New York DOH approved at any Patient History for Mucopolysaccharidosis (MPS) Testing laboratory. An approved NPL form must accompany specimen. Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) **Performed:** Varies **Reported:** 2-3 weeks Specimen Required: Patient Prep: N/A Collect: Lavender (K2EDTA, K3EDTA), Plain Red, or Serum Separator Tube (SST). Specimen Preparation: Transfer 500 µL serum or plasma to ARUP Standard transport Tube and freeze immediately. (Min 250 µL) Storage/Transport Temperature: Critical Frozen Remarks: N/A Unacceptable Conditions: Plasma collected in green (heparin) tube. Ambient or Refrigerated Specimens Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month (avoid repeated

freeze /thaw cycles)

Reference Interval: By report

Interpretive Data:

Total Heparan Sulfate, Serum/Plasma is a sum of the internal disaccharides D0A0 and D0S0. NRE = Non Reducing End

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 83864

New York DOH approval pending. Call for status update.



New Test	<u>3003552</u>	3003552 Mucopolysaccharidoses Type 1/2, Total Heparan Sulfate and NRE (Sensi-Pro®) Ouantitative, Urine		MPS 1/2 U	
Available Now Click for Pricin	, <u>ng</u>				
四 二 四二 一	Patient History (MPS) Testing	for Mucopolysaccharidosis	以 一 一 一	Test not New York DOH app laboratory. An approved NPI accompany specimen.	roved at any form must
Methodology:	Liquid Chromato	graphy-Tandem Mass Spectrometry (LC-MS/MS)		
Performed:	Varies				
Reported:	2-3 weeks				
Specimen Requir	ed: Patient Prep: First	catch urine is preferred.			
	Collect: Urine				
	Specimen Prepara	tion: Transfer 2mL urine to ARUP St	tandard transport T	ube and freeze immediately. (Min 1 mI	<u>.)</u>
	Storage/Transport	Temperature: Frozen			
	<u>Remarks:</u> N/A				
	Unacceptable Con	iditions: Specimens containing preser	vatives or heparin		
	Stability (collection	<u>on to initiation of testing):</u> Ambient: U	Jnacceptable; Refri	gerated: Unacceptable; Frozen: 1 mont	h (avoid repeated
	Treeze /thaw cycle	·S)			

Reference Interval: By report

Interpretive Data:

Refer to report.

Total Heparan Sulfate, Urine is a sum of the internal disaccharides D0A0 and D0S0. NRE = Non Reducing End

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 83864

New York DOH approval pending. Call for status update.



New Test3003487Mucopolysaccharidoses Type 4A/6 Total Chondroitin Sulfate and
Dermatan Sulfate with NRE (Sensi-Pro®) Quantitative, SerumMPS 4A/6 S

Available Now Click for Pricing



Patient History for Mucopolysaccharidosis (MPS) Testing



Test not New York DOH approved at any laboratory. An approved NPL form must accompany specimen.

Methodology:	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Performed:	Varies
Reported:	2-3 weeks
Specimen Require	1: <u>Patient Prep:</u> N/A
	Collect: Serum (Serum Separator Tube (SST)).
	Specimen Preparation: Transfer 500 µL serum to ARUP Standard transport Tube and freeze immediately. (Min 300 µL)
	Storage/Transport Temperature: Frozen
	Remarks: N/A
	Unacceptable Conditions: N/A
	Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 4 month (3 freeze thaw cycles are
	acceptable)

Reference Interval:

Interpretive Data:

Total Chondroitin Sulfate (CS) and Dermatan Sulfate (DS), Serum is a sum of the internal disaccharides D0a0, D0a4, and D0a6. NRE = Non Reducing End

This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 83864

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

By report



New Test	<u>3003539</u>	Mucopolysaccharidoses (Sensi-Pro®) Quantitativ	Type 4A/6 Tot /e, Urine	al CS-DS and NRE	MPS 4A/6 U
Available Now Click for Pricin	, <u>1g</u>	``````````````````````````````````````			
	Patient History for (MPS) Testing	r Mucopolysaccharidosis		Test not New York DOI laboratory. An approved accompany specimen.	H approved at any I NPL form must
Methodology:	Liquid Chromatogra	nphy-Tandem Mass Spectrometry (LC-MS/MS)		
Performed:	Varies				
Reported:	2-3 weeks				
Specimen Require	ed: Patient Prep: N/A				
	Collect: Urine				
	Specimen Preparation	on: Transfer 0.25 mL urine to poly	propylene sample tu	be and freeze immediately. (Min	n 0.15 mL)
	Storage/Transport T	emperature: Critical Frozen			
	<u>Remarks:</u> N/A		<u> </u>		
	Unacceptable Cond	<u>itions:</u> Specimens containing preser	rvatives or heparin		
	Stability (collection	to initiation of testing): Ambient:	Unacceptable; Refri	gerated: Unacceptable; Frozen:	I year (3 freeze thaw cycl
	are acceptable)				

Reference Interval: By report

Interpretive Data:

Refer to report.

Total Chondroitin Sulfate and Dermatan Sulfate, Urine is a sum of the internal disaccharides D0a0, D0a4, and D0a6. NRE = Non Reducing End

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 83864

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

0092168 Niacin (Vitamin B₃)

NIACIN B3

Specimen Required: Collect: Lavender (K₂ or K₃ EDTA).

Specimen Preparation: Protect from light. Transfer 4 mL plasma to an ARUP Amber Transport Tube (ARUP supply #54457) available online through eSupply using ARUP ConnectTM or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered. Storage/Transport Temperature: Frozen Unacceptable Conditions: Specimens not protected from light. Grossly hemolyzed or lipemic specimens.

<u>Stability (collection to initiation of testing):</u> Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 2 months



0080440 Oligoclonal Band Profile

OLIGO

Methodology: Qualitative Isoelectric Focusing/Electrophoresis/Quantitative Immunoturbidimetry

 Specimen Required:
 Collect: CSF AND serum separator tube or plain red. Serum specimen should be drawn within 48 hours of CSF collection.

 Specimen Preparation:
 Allow serum to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transport 1.5 mL CSF. (Min: 1.0 mL) AND transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.6 mL)

 Storage/Transport Temperature:
 Refrigerated.

 Unacceptable Conditions:
 Grossly bloody or hemolyzed specimens or severe lipemia.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 2 week; Frozen: 6 months

Reference Interval:

Test Number	Components	Reference Interval	
0050350	Immunoglobulin G	Effective February 16, 2021	
		0-2 years: 242-1108 mg/dL	
		3-4 years: 485-1160 mg/dL	
		5-9 years: 514-1672 mg/dL	
		10-14 years: 581-1652 mg/dL	
		15-18 years: 479-1433 mg/dL	
		19 years or older: 768-1632 mg/dL	
3003485	Immunoglobulin G, CSF	0.0-6.0 mg/dL	
0050200 Albumin, CSF		0-35 mg/dL	
	Albumin Index	0.0-9.0	
CSF IgG/Albumin Ratio		0.09-0.25	
	IgG Index	0.28-0.66	
	CSF Oligoclonal Bands	Negative	
	Interpretation	By report	
	CSF IgG Synthesis Rate	Less than or equal to 8.0 mg/d	
0050671	Albumin Serum	3500-5200 mg/dL	
	Oligoclonal Bands Number, CSF	0 - 1 Bands	

HOTLINE NOTE: There is a clinically significant charting name change associated with this test. Change the charting name for component 0050671, Albumin by Nephelometry from Albumin by Nephelometry to Albumin Serum.

0081135 Oligoclonal Bands in CSF and Serum

OLIGOB

Specimen Required: Collect: CSF AND serum separator tube or plain red. Serum specimen should be drawn within 48 hours of CSF collection. Specimen Preparation: Allow serum to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transport 1.5 mL CSF (Min: 0.7 mL) AND transfer 1 mL serum to an ARUP Standard Transport Tube (Min: 0.6 mL). Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Grossly bloody or hemolyzed specimens or severe lipemia.

Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 6 months



2007479 Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

PAIN HYB U

Reference Interval: Effective February 16, 2021

Drugs covered and range of cutoff concentrations. Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.

Drugs/Drug Classes	Range of Cutoff Concentrations
Barbiturates	200 ng/mL
Benzodiazepine-like:	20-60 ng/mL
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam,	
temazepam, zolpidem	
Cannabinoids (11-nor-9-carboxy-THC)	20 ng/mL
Ethyl Glucuronide	500 ng/mL
Muscle Relaxant(s):	100 ng/mL
carisoprodol, meprobamate	
Opiates/Opioids:	2-200 ng/mL
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine,	
methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol	
GABA analogues:	100 ng/mL
Gabapentin, pregabalin	
Phencyclidine (PCP)	25 ng/mL
Stimulants:	50-200 ng/mL
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy),	
MDEA (Eve), MDA, phentermine	

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 2007647, Hydromorphone (cutoff 40 ng/mL) from Hydromorphone (cutoff 40 ng/mL) to Hydromorphone (cutoff 20 ng/mL).

Change the charting name for component 2007662, Amphetamine (cutoff 100 ng/mL) from Amphetamine (cutoff 100 ng/mL) to Amphetamine (cutoff 50 ng/mL).

Change the charting name for component 2007663, Methamphetamine (cutoff 400 ng/mL) from Methamphetamine (cutoff 400 ng/mL) to Methamphetamine (cutoff 200 ng/mL).

There is a component change associated with this test.

Add component 3003502, Naloxone (cutoff 100 ng/mL)

Add component 3003499, Alpha-OH-Midazolam (cutoff 20 ng/mL)

Add component 3003500, Zolpidem Metabolite (cutoff 100 ng/mL)

Add component 3003501, Gabapentin (cutoff 100 ng/mL)

Add component 3003503, Pregabalin (cutoff 100 ng/mL)

Remove component 2007659, Propoxyphene (cutoff 300 ng/mL)



2009288 Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and **Enzyme Immunoassay, Urine**

Reference Interval: Effective February 16, 2021

Drugs covered and range of cutoff concentrations.

Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.

Drugs/Drug Classes	Range of Cutoff Concentrations
Barbiturates	200 ng/mL
Benzodiazepine-like:	20 - 60 ng/mL
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam,	
temazepam, zolpidem	
Cannabinoids (11-nor-9-carboxy-THC)	20 ng/mL
Ethyl Glucuronide	500 ng/mL
Muscle Relaxant(s):	100 ng/mL
carisoprodol, meprobamate	
Opiates/Opioids:	2-200 ng/mL
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine,	
methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol	
GABA analogues:	100 ng/mL
Gabapentin, pregabalin	
Phencyclidine (PCP)	25 ng/mL
Stimulants:	50-200 ng/mL
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy),	
MDEA (Eve), MDA, phentermine	

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 2007647, Hydromorphone (cutoff 40 ng/mL) from Hydromorphone (cutoff 40 ng/mL) to Hydromorphone (cutoff 20 ng/mL).

Change the charting name for component 2007662, Amphetamine (cutoff 100 ng/mL) from Amphetamine (cutoff 100 ng/mL) to Amphetamine (50 ng/mL). Change the charting name for component 2007663, Methamphetamine (cutoff 400 ng/mL) from Methamphetamine (cutoff 400 ng/mL) to Methamphetamine (cutoff 200 ng/mL).

There is a component change associated with this test.

Add component 3003502, Naloxone (cutoff 100 ng/mL)

Add component 3003499, Alpha-OH-Midazolam (cutoff 20 ng/mL)

Add component 3003500, Zolpidem Metabolite (cutoff 100 ng/mL)

Add component 3003501, Gabapentin (cutoff 100 ng/mL)

Add component 3003503, Pregabalin (cutoff 100 ng/mL)

Remove component 2007659, Propoxyphene (cutoff 300 ng/mL)

3000455 Ph-Like Acute Lymphoblastic Leukemia (ALL) Panel by FISH

F PHLK ALL

HOTLINE NOTE: Name change only.

2002871 PML-RARA Detection by RT-PCR, Quantitative

PML ONT

HOTLINE NOTE: There is a component change associated with this test. Add component 3003498, PML-RARA Translocation Source

PAIN HYB 2



2002109 Protein Electrophoresis with Reflex to Immunofixation, Serum

SPEP REFLEX

Methodology:

Quantitative Capillary Electrophoresis/Qualitative Immunofixation Electrophoresis/Quantitative Immunoturbidimetry/Quantitative Spectrophotometry

Reference Interval:

Test Number	Components	Reference Interval			
0050640	Protein Electrophoresis,	Effective August 19, 2019			
	Serum	Test Number	Components	Reference Interval	
			Total Protein, Serum	Refer to report	
			Albumin	Refer to report	
			Alpha-1 Globulins	Refer to report	
			Alpha-2 Globulins	Refer to report	
			Beta Globulins	Refer to report	
			Gamma	Refer to report	
0050350	Immunoglobulin G	Effective February	16, 2021		
0-2 years: 242-1108 mg/dL 3-4 years: 485-1160 mg/dL 5-9 years: 514-1672 mg/dL 10-14 years: 581-1652 mg/dL 15-18 years: and older: 768-1632 mg/dL 19 years and older: 768-1632 mg/dL					
0050340	Immunoglobulin A	Effective February 16, 2021			
		0-2 years: 2-126 m 3-4 years: 14-212 r 5-9 years: 52-226 r 10-14 years: 42-34 15-18 years: 60-34 19 years and older:	g/dL ng/dL 5 mg/dL 9 mg/dL 68-408 mg/dL		
0050355	Immunoglobulin M	Effective February	16, 2021		
		0-2 years: 21-215 r 3-4 years: 26-155 r 5-9 years: 26-188 r 10-14 years: 47-25 15-18 years: 26-23 19 years and older:	ng/dL ng/dL ng/dL 2 mg/dL 2 mg/dL 35-263 mg/dL		

RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Detection, Quantitative <u>2010138</u>

AML1-ETO Q

HOTLINE NOTE: There is a component change associated with this test. Add component 3003497, RUNX1-RUNX1T1 Source



New Test	<u>3003504</u>	Squamous Cell Carcinoma, Serum	SCC S
Click for Pricing			
Methodology:	Immunofluoresco	ence	
Performed:	Tue		
Reported:	1-8 days		
Specimen Required:	Collect: Serum s	separator tube or plain red.	
	Specimen Prepar	ration: Allow specimen to clot completely at room temperature. Separate serum from cells	ASAP or within 2 hours of
	collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)		
	Storage/Transpor	vrt Temperature: Frozen.	
	Unacceptable Co	onditions: Specimens exposed to repeated freeze/thaw cycles.	
	Stability (collect	tion to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated:	14 days; Frozen: 2 months

Reference Interval:

0.0-1.7 ng/mL

Interpretive Data:

This test is performed using the BRAHMS SCC Kryptor kit. Results obtained with different assay methods or kits cannot be used interchangeably. SCC Antigen levels alone should not be interpreted as evidence of the presence or absence of malignant disease. In patients with known or expected cancer, other tests and procedures must be considered for diagnosis and patient management. Elevated concentrations may also occur in benign conditions such as gynecological diseases, inflammatory lung disease, and liver or renal insufficiency.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 86316

New York DOH Approved.

0092582	Stachybotrys chartarum/atra Panel II	STACHPANII
Performed:	Varies	
Reported:	5-10 days	
2003128	Tapentadol and Metabolite, Urine, Quantitative	TAPENTA UR
Performed:	Mon	
Reported:	1-8 days	
Specimen Requir	ed: <u>Collect:</u> Random urine. <u>Specimen Preparation:</u> Transfer 2 mL urine with no additives or preservatives to a <u>Storage/Transport Temperature:</u> Refrigerated. <u>Unacceptable Conditions:</u> Specimens exposed to repeated freeze/thaw cycles. <u>Stability (collection to initiation of testing)</u> : Ambient: 1 week; Refrigerated: 1 more	an ARUP Standard Transport Tube. (Min: 1 mL) nth; Frozen: 3 years.



New Test	<u>3003458</u>	Trypsin by Immunohistochemistry	
----------	----------------	---------------------------------	--

TRYPS IHC

Available Now Click for Pricing

Methodology:	Immunohistochemistry
Performed:	Mon-Fri
Reported:	1-3 days

Specimen Required: Collect: Tissue.

Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit (recommended but not required), (ARUP supply #47808) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787. (Min: 2 slides) If sending precut slides, do not oven bake.

<u>Storage/Transport Temperature:</u> Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. <u>Unacceptable Conditions:</u> Specimens submitted with non-representative tissue type. Depleted specimens. <u>Stability (collection to initiation of testing)</u>: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Note: This test is performed as a stain and return (technical) service only.

CPT Code(s): 88342

New York DOH Approved.



New Test	<u>3002100</u>	Tuberous Sclerosis Complex Panel, Sequencing and Deletion/Duplication	TSC NGS
Available Now			
Click for Pricing			
Methodology:	Massively Parallel	l Sequencing/Genomic Microarray (Oligo-based Array)	
Performed:	Varies		
Reported:	3-6 weeks		
Specimen Required:	Collect: Lavender Specimen Prepara Storage/Transport Unacceptable Con Stability (collectio	(EDTA) or Yellow (ACD Solution A or B). <u>tion:</u> Transport 3 mL whole blood. (Min: 1.5 mL) <u>Temperature:</u> Refrigerated. <u>iditions:</u> Serum or plasma; grossly hemolyzed or frozen specimens <u>in to initiation of testing)</u> : Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable	
Reference Interva	l: By rep	ort	
Interpretive Data: Refer to report.	:		
This test was develop Drug Administration.	ed and its performa This test was perfo	nce characteristics determined by ARUP Laboratories. It has not been cleared or approved by the ormed in a CLIA certified laboratory and is intended for clinical purposes.	US Food and

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Genes tested: TSC1, TSC2

CPT Code(s): 81405, 81406, 81407

New York DOH approval pending. Call for status update.



New Test	<u>3002096</u>	Tuberous Sclerosis Complex Panel, Sequencing and Deletion/Duplication, Fetal	TSC NGS FE
Available Now Click for Pricing		•	
Methodology: Performed:	Massively Parall Varies	lel Sequencing/Genomic Microarray (Oligo-based Array)	
Reported:	2-4 weeks, if cul	lture is required an additional 1 to 2 weeks is required for processing time	
Specimen Required:	Collect: Fetal Sp to culture, this of AND Maternal Specimen Prepar percent confluen complete. AND Maternal Storage/Transpo within 48 hours Maternal Cell Of Stability (collect Frozen: Unaccep Maternal Cell O	 pecimen: Four (4) T-25 flasks at 80 percent confluent of cultured amniocytes or cultured and percent confluent of cultured amniocytes or cultured and percent confluent of cultured amniocytes or cultured and cultured amniocytes or Cultured CVS: Fill flasks with culture media. Tran at of cultured cells filled with culture media. Backup cultures must be retained at the cell Contamination Specimen: Transport 3 mL whole blood (Min: 1 mL) rt Temperature: Culture Amniocytes or Cultured CVS: CRITICAL ROOM TEMPI of shipment due to lability of cells. Contamination Specimen: Room temperature. ion to initiation of testing): Culture Amniocytes or Cultured CVS: Ambient: 48 holy other is a contamination specimen. 	red CVS. If the client is unable ACD Solution A or B). sport four (4) T-25 flasks at 80 lient's institution until testing is ERATURE. Must be received urs; Refrigerated: Unacceptable; ptable
Reference Interva	l: By re	port	

Interpretive Data:

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Reported times are based on receiving the four T-25 flasks at 80 percent confluent. Cell culture time is independent of testing turn-around time. Maternal specimen is recommended for proper test interpretation. Order Maternal Cell Contamination.

Genes tested: TSC1 TSC2

CPT Code(s): 81405; 81406; 81407; 81265

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

2003184 Vitamin B₇ (Biotin)

B7

Specimen Required: Collect: Plain red or serum separator tube (SST).

 Specimen Preparation: Protect from light. Allow specimen to clot for 30 minutes and separate from cells. Transfer 2 mL serum to an ARUP Amber Transport Tube (ARUP supply #54457) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)

 Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.

 Storage/Transport Temperature: Frozen

 Unacceptable Conditions: Grossly hemolyzed or lipemic specimens. Specimens not protected from light.

 Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 2 weeks



2007136 von Willebrand Factor (VWF) Collagen Binding

VWF C BIND

Methodology:	Enzyme-Linked Immunosorbent Assay
Performed:	Varies
Reported:	3-9 days

Specimen Required: Collect: Light Blue (CTAD).

Specimen Preparation: Transfer 1.0 mL citrated plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
 Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
 Storage/Transport Temperature: CRITICAL FROZEN.
 Unacceptable Conditions: Hemolyzed specimens.
 Stability (collection to initiation of testing): Ambient: 24 hours; Refrigerated: 24 hours; Frozen: 3 weeks

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 2007137, von Willebrand Factor Collagen Binding from von Willebrand Factor Collagen Binding to VWF Collagen Binding.

There is a component change associated with this test. Add component 3003442, VWF Ratio



The following will be discontinued from ARUP's test menu on February 16, 2021. Replacement test options are supplied if applicable.

Test Number	Test Name	Refer To Replacement	
0050671	Albumin by Nephelometry	Albumin, Serum or Plasma by Spectrophotometry (0020030)	
0051786	Alport Syndrome, X-linked (COL4A5) Sequencing		
2010113	Beta Globin (HBB) Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
2011450	Carisoprodol and Meprobamate, Serum or Plasma, Quantitative		
2012717	CHARGE Syndrome (CHD7) Sequencing, Fetal		
2012609	CHARGE Syndrome, CHD7 Sequencing		
2010696	EIF2AK4-Associated Disorders (EIF2AK4) Sequencing		
0051001	Hereditary Hemorrhagic Telangiectasia (ACVRL1 and ENG)		
0051381	Sequencing		
2012482	HLA-A by Next Generation Sequencing		
2012486	HLA-B by Next Generation Sequencing		
2012490	HLA-C by Next Generation Sequencing		
2012502	HLA-DPB1 by Next Generation Sequencing		
2012498	HLA-DQB1 by Next Generation Sequencing		
2001728	HNPCC/Lynch Syndrome Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
0050525	Immunoglobulin A. Saliya	Immunoglobulin A (0050340)	
0099200	Immunoglobulin D. Serum	Immunoglobulin D. Serum (3003486)	
0050571	Immunoglobulin G Subclass 1	Immunoglobulin G Subclasses (1, 2, 3, 4) (0050577)	
0050572	Immunoglobulin G Subclass 2	Immunoglobulin G Subclasses (1, 2, 3, 4) (0050577)	
0050573	Immunoglobulin G Subclass 3	Immunoglobulin G Subclasses (1, 2, 3, 4) (0050577)	
0050670	Immunoglobulin G. CSF	Immunoglobulin G, CSF (3003485)	
2004680	Interleukin 28 B (IL28B)-Associated Variants, 2 SNPs		
2002888	Kappa/Lambda Light Chain Panel by in situ Hybridization, Paraffin	Kappa/Lambda Light Chain Panel by in situ Hybridization on Paraffin (3003506)	
<u>2013595</u>	Kappa/Lambda Light Chain Panel by In Situ Hybridization, Stain Only	Kappa/Lambda Light Chain Panel by In Situ Hybridization Stain Only (3003525)	
<u>3001379</u>	Liver Fibrosis - FibroMeter Vibration Controlled Transient Elastography (FibroMeter plus FibroScan VCTE)		
2011521	Meprobamate, Serum or Plasma, Quantitative		
	Mucopolysaccharidosis Type 1, Total HS and NRE (Sensi-Pro®)	Mucopolysaccharidoses Type 1/2, Total HS and NRE (Sensi-Pro®)	
2007599	Quantitative. Serum or Plasma	Ouantitative. Serum or Plasma (3003566)	
2007.000	Mucopolysaccharidosis Type 1, Total HS and NRE (Sensi-Pro®)	Mucopolysaccharidoses Type 1/2, Total HS and NRE (Sensi-Pro®)	
<u>2007488</u>	Quantitative, Urine	Quantitative, Urine (3003552)	
2000775	Mucopolysaccharidosis Type II, Total HS and NRE (Sensi-Pro®)	Mucopolysaccharidoses Type 1/2, Total HS and NRE (Sensi-Pro®)	
2008775	Quantitative, Serum or Plasma	Quantitative, Serum or Plasma (3003566)	
2000282	Mucopolysaccharidosis Type II, Total HS and NRE (Sensi-Pro®)	Mucopolysaccharidoses Type 1/2, Total HS and NRE (Sensi-Pro®)	
2009282	Quantitative, Urine	Quantitative, Urine (3003552)	
2001952	Neurofibromatosis Type 1 (NF1) Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
2004180	Noonan Syndrome (PTPN11) Sequencing with Reflex to (SOS1)		
2004189	Sequencing		
0099289	Organic Acids, Plasma	Organic Acids, Urine (0098389)	
3001760	Pancreatitis (PRSS1) Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
<u>3001764</u>	Pancreatitis (SPINK1) Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
<u>0051682</u>	Primary Carnitine Deficiency (SLC22A5) Sequencing		
3001395	SHOX-Related Disorders, Deletion/Duplication	Deletion/Duplication Analysis by MLPA (3003144)	
0081054	Squamous Cell Carcinoma Antigen, Serum	Squamous Cell Carcinoma, Serum (3003504)	